INDEX TO AUTHORS

A

ABBOTT, J. See YAMAZAKI, BOYSE, MIKÉ, THALER, MATHIESON, ABBOTT, BOYSE, ZAYAS, and THOMAS 1324

ABDIN, Z. H. See HUSBY, VAN DE RIJN, ZABRISKIE, ABDIN, and WILLIAMS 1094

ABPLANALP, HANS. See CHANH, BENEDICT, and ABPLANALP 555

ACS, GEORGE. See KYNER, ZABOS, CHRISTMAN, and ACS 1674

ADAMS, ERIC P. See ENGLISH, ADAMS, and MORRIS 586

ADELMAN, BURT. See JAFFE, MINICK, ADELMAN, BECKER, and NACHMAN 209

ALBRIGHT, JULIA W., and MAKINODAN, TAKASHI. Decline in the growth potential of spleen-colonizing bone marrow stem cells of long-lived aging mice 1204

ALPER, CHESTER A. Inherited structural polymorphism in human C2: evidence for genetic linkage between *C2* and *Bf* 1111

ANDERS, R. F. See LINDER, ANDERS, and NATVIG 1336

ARBEIT, ROBERT D. See DICKLER, ARBEIT, HENKART, and SACKS 282

ASHERSON, G. L. See THOMAS, ASHERSON, and WATKINS 1386

ASOFSKY, RICHARD. See SCHER, SHARROW, WISTAR, ASOFSKY, and PAUL 494

AUSTEN, K. F. See GOETZL and AUSTEN 1424

B

BACH, FRITZ H., JARRETT-TOTH, ESTHER, BENIKE, CLAUDIA J., SHEEHY, MICHAEL J., SONDEL, PAUL M., and BACH, MARILYN L. Three HLA-D region antigens defined by primed LD typing 549

—. See LINDAHL and BACH 305

BACH, MARILYN L. See BACH, JARRETT-TOTH, BENIKE, SHEEHY, SONDEL, and BACH 549

BAGGIOLINI, M. See VISCHER, BRETZ, and BAGGIOLINI 863

BALTIMORE, DAVID. See SILVERSTONE, CANTOR, GOLDSTEIN, and BALTIMORE 543

BANDU, MARIE-THÉRÈSE. See GRESSER, TOVEY, BANDU, MAURY, and BROUTY-BOYÉ 1305

—. See GRESSER, TOVEY, MAURY, and BANDU 1316

BAUER, EUGENE A. See LICHTENSTEIN, BAUER, HOYT, and WEDNER 145

BEAN, MICHAEL A. See SHIKU, TAKAHASHI, BEAN, OLD, and OETTGEN 1116

BECHTOL, KATHLEEN B., and MCDEVITT, HUGH O. Antibody response of C3H←→(CKB × CWB)F_1 tetraparental mice to poly-L(Tyr,Glu)-poly-D,L-Ala--poly-L-Lys immunization 123

BECKER, CARL G., and HARPEL, PETER C. α_2-Macroglobulin on human vascular endothelium 1

—. See JAFFE, MINICK, ADELMAN, BECKER, and NACHMAN 209

BECKER, E. L. See HENSON, GOULD, and BECKER 1657

BEER, ALAN E. See PARMELY, BEER, and BILLINGHAM 358

BENACERRAF, BARUJ. See BURAKOFF, GERMAIN, and BENACERRAF 1609

—. See DEBRÉ, WALTENBAUGH, DORF, and BENACERRAF 272, 277

—. See PIERCE, KAPP, and BENACERRAF 371

BENEDICT, ALBERT A. See CHANH, BENEDICT, and ABPLANALP 555

BENGALI, KATHLEEN. See IHLE, MCEWAN, and BENGALI 1391

BENIKE, CLAUDIA J. See BACH, JARRETT-TOTH, BENIKE, SHEEHY, SONDEL, and BACH 549

BEREK, CLAUDIA, TAYLOR, B. A., EICHMANN, K. Genetics of the idiotype of BALB/c myeloma S117: multiple chromosomal loci for V_H genes encoding specificity for Group A streptococcal carbohydrate 1164

BETZ, SALLY J. See MORRISON, BETZ, and JACOBS 840

BIANCO, CELSO, EDEN, ALINE, and COHN, ZANVIL A. The induction of macrophage spreading: role of coagulation factors and the complement system 1531

BILLING, RONALD, RAFIZADEH, BAHMAN, DREW, IAN, HARTMAN, GARY, GALE, ROBERT, and TERASAKI, PAUL. Human B-lymphocyte antigens expressed by lymphocytic and myelocytic leukemia cells. I. Detection by rabbit antisera 167

BILLINGHAM, RUPERT E. See PARMELY, BEER, and BILLINGHAM 358

BINZ, HANS, and WIGZELL, HANS. Specific transplantation tolerance induced by autoimmunization against the individual's own, naturally occurring idiotypic, antigen-binding receptors 1438

BLANDEN, ROBERT V. See ZINKERNAGEL, DUNLOP, BLANDEN, DOHERTY, and SHREFFLER 519

BÖSING-SCHNEIDER, RITA, and HAUG, MARGARETE. Induction and abrogation of unresponsiveness in nude mouse cells 1458

BOYSE, EDWARD A. See GORDON, MATHIESON, SAMELSON, BOYSE, and SIMPSON 810
—. See HERZENBERG, OKUMURA, CANTOR, SATO, SHEN, BOYSE, and HERZENBERG 330
—. See HUBER, CANTOR, SHEN, and BOYSE 1128
—. See OBATA, STOCKERT, BOYSE, TUNG, and LITMAN 533
—. See VADAS, MILLER, MCKENZIE, CHISM, SHEN, BOYSE, GAMBLE, and WHITELAW 10
—. See YAMAZAKI, BOYSE, MIKÉ, THALER, MATHIESON, ABBOTT, BOYSE, ZAYAS, and THOMAS 1324
BOYSE, J. See YAMAZAKI, BOYSE, MIKÉ, THALER, MATHIESON, ABBOTT, BOYSE, ZAYAS, and THOMAS 1324
BRAUN, JONATHAN. See SCHREINER, BRAUN, and UNANUE 1683
BRETZ, U. See VISCHER, BRETZ, and BAGGIOLINI 863
BROUTY-BOYÉ, DANIÈLE. See GRESSER, TOVEY, BANDU, MAURY, and BROUTY-BOYÉ 1305
BROWN, MICHAEL S. See HO, BROWN, KAYDEN, and GOLDSTEIN 444
BURAKOFF, STEVEN J., GERMAIN, RONALD N., and BENACERRAF, BARUJ. Cross-reactive lysis of trinitrophenyl-derivatized *H-2* incompatible target cells by cytolytic T lymphocytes generated against syngeneic TNP spleen cells 1609

C

CALDERON, JESUS. See UNANUE, KIELY, and CALDERON 155
CAMBIER, JOHN C., KETTMAN, JOHN R., VITETTA, ELLEN S., and UHR, JONATHAN W. Differential susceptibility of neonatal and adult murine spleen cells to in vitro induction of B-cell tolerance 293
CANCRO, MICHAEL, and POTTER, MICHAEL. The requirement of an adherent cell substratum for the growth of developing plasmacytoma cells in vivo 1554
CANTOR, HARVEY. See HERZENBERG, OKUMURA, CANTOR, SATO, SHEN, BOYSE, and HERZENBERG 330
—. See HUBER, CANTOR, SHEN, and BOYSE 1128
—. See SILVERSTONE, CANTOR, GOLDSTEIN, and BALTIMORE 543
CARMICHAEL, L. E. See MCGREGOR, LOGIE, and CARMICHAEL 627
CHANH, TRAN CONG, BENEDICT, ALBERT A., and ABPLANALP, HANS. Association of serum hemolytic complement levels with the major histocompatibility complex in chickens 555
CHESS, LEONARD, EVANS, R., HUMPHREYS, R. E., STROMINGER, J. L., and SCHLOSSMAN, S. F. Inhibition of antibody-dependent cellular cytotoxicity and immunoglobulin synthesis by an antiserum prepared against a human B-cell Ia-like molecule 113
—. See HUMPHREYS, MCCUNE, CHESS, HERRMAN, MALENKA, MANN, PARHAM, SCHLOSSMAN, and STROMINGER 98
CHISM, S. E. See VADAS, MILLER, MCKENZIE, CHISM, SHEN, BOYSE, GAMBLE, and WHITELAW 10
CHOI, Y. S. See FAANES, WALKER, and CHOI 1284
CHRISTMAN, JUDITH. See KYNER, ZABOS, CHRISTMAN, and ACS 1674
CLAFLIN, J. LATHAM. See RUDIKOFF and CLAFLIN 1294
COHEN, J. JOHN, and FAIRCHILD, SALLY S. T-lymphocyte precursors. I. Synergy between precursor and mature T lymphocytes in the response to concanavalin A 456
COHEN, JOEL E. See D'EUSTACHIO, COHEN, and EDELMAN 259
COHN, ZANVIL A. See BIANCO, EDEN, and COHN 1531
—. See EDELSON and COHN 1581, 1596
COLTEN, HARVEY R. See ZEIGER, TWAROG, and COLTEN 1049
COOPER, MAX D. See LYDYARD, GROSSI, and COOPER 79
COOPER, NEIL R., JENSEN, FRED C., WELSH, RAYMOND M., JR., and OLDSTONE, MICHAEL B. A. Lysis of RNA tumor viruses by human serum: direct antibody-independent triggering of the classical complement pathway 970
COOPER, RICHARD A. See GUERRY, KENNA, SCHREIBER, and COOPER, 1695
CURTIS, J. E. See LOUIE, CURTIS, TILL, and MCCULLOCH 1243

D

DAILEY, MORRIS O. See JANEWAY, MAURER, DAILEY, and INMAN 1621
DAVID, CHELLA S. See TADA, TANAGUCHI, and DAVID 713
DEBRÉ, PATRICE, WALTENBAUGH, CARL, DORF, MARTIN, and BENACERRAF, BARUJ. Genetic control of specific immune suppression. III. Mapping of *H-2* complex complementing genes controlling immune suppression by the random copolymer L-glutamic acid^{50}-L-tyrosine^{50} (GT) 272
—, —, —, and —. IV. Responsiveness to the random copolymer L-glutamic acid^{50}-L-tyrosine^{50} induced in BALB/c mice by cyclophosphamide 277
D'EUSTACHIO, PETER, COHEN, JOEL E., and EDELMAN, GERALD M. Variation and control of specific antigen-binding cell populations in individual fetal mice 259
DE WECK, A. L. See GECZY, GECZY, and DE WECK 226
DICKLER, HOWARD B., ARBEIT, ROBERT D., HENKART, PIERRE A., and SACHS, DAVID H. Association between Ia antigens and the Fc receptors of certain T lymphocytes 282

DILLNER, M-L. See HELLSTRÖM, DILLNER, HAMMARSTRÖM, and PERLMANN 1381
DI PAULI, RAIMUND. See KOLB, DI PAULI, and WEILER 1031
DOHERTY, PETER C. See ZINKERNAGEL, DUNLOP, BLANDEN, DOHERTY, and SHREFFLER 519
DORF, MARTIN. See DEBRÉ, WALTENBAUGH, DORF, and BENACERRAF 272, 277
DREW, IAN. See BILLING, RAFIZADEH, DREW, HARTMAN, GALE, and TERASAKI 167
DUNLOP, MALCOLM B. C. Se ZINKERNAGEL, DUNLOP, BLANDEN, DOHERTY, AND SHREFFLER 519
DURDA, PAUL J., and GOTTLIEB, PAUL D. The Ly-3 antigens on mouse thymocytes: immune precipitation and molecular weight characterization 476

E

EADY, R. P. See HOUGH, EADY, HAMBLIN, STEVENSON, and STEVENSON 960
ECONOMOU, JAMES S. See SHIN, ECONOMOU, PASTERNACK, JOHNSON, and HAYDEN 1274
EDELMAN, GERALD M. See D'EUSTACHIO, COHEN, and EDELMAN 259
—. See MCCLAIN and EDELMAN 1494
EDELSON, PAUL J., and COHN, ZANVIL A. 5'-Nucleotidase activity of mouse peritoneal macrophages. I. Synthesis and degradation in resident and inflammatory populations 1581
— and —. II. Cellular distribution and effects of endocytosis 1596
EDEN, ALINE. See BIANCO, EDEN, and COHN 1531
EICHMANN, K. See BEREK, TAYLOR, and EICHMANN 1164
EINARSON, BRETT L. See LINDSTROM, EINARSON, LENNON, and SEYBOLD 726
ELLIOTT, BRUCE E. See NAGY, ELLIOTT, and NABHOLZ 1545
ENGEL, ANDREW G. See LINDSTROM, ENGEL, SEYBOLD, LENNON, and LAMBERT 739
ENGLISH, LEONARD S., ADAMS, ERIC P., and MORRIS, BEDE. The synthesis and secretion of immunoglobulins by lymphoid cells in the sheep. The primary response to Salmonella lipopolysaccharide 586
EVANS, R. See CHESS, EVANS, HUMPHREYS, STROMINGER, and SCHLOSSMAN 113

F

FAANES, R., WALKER, M., and CHOI, Y. S. Isoantiserum-augmented development of lymphocyte-mediated cytotoxicity 1284
FAIRCHILD, SALLY S. See COHEN and FAIRCHILD 456
FAUCI, ANTHONY S., and PRATT, KAREN R. Activation of human B lymphocytes. I. Direct plaque-forming cell assay for the measurement of polyclonal activation and antigenic stimulation of human B lymphocytes 674
FISCHETTI, V. A., GOTSCHLICH, E. C., SIVIGLIA, G., and ZABRISKIE, J. B. Streptococcal M protein extracted by nonionic detergent. I. Properties of the antiphagocytic and type-specific molecules 32
FØRRE, Ø., NATVIG, J. B., and KUNKEL, H. G. Serological detection of variable region (V_H) subgroups of Ig heavy chains 897
FRANKLIN, EDWARD C. Some properties of antisera to serum amyloid A protein (SAA): inhibition of precipitation by complexing of SAA to albumin 1679
FRASCH, C. E., PARKES, L., MCNELIS, R. M., and GOTSCHLICH, E. C. Protection against group B meningococcal disease. I. Comparison of group-specific and type-specific protection in the chick embryo model 319
FRELINGER, JEFFREY A., NIEDERHUBER, JOHN E., and SHREFFLER, DONALD C. Effects of anti-Ia sera on mitogenic responses. III. Mapping the genes controlling expression of Ia determinants on concanavalin A-reactive cells to the *I-J* subregion of the *H-2* gene complex 1141
FUKASAWA, TAKUTA. See NARUSE, FUKASAWA, HIROKAWA, OIKE, and MIYAKAWA 1347

G

GALE, ROBERT. See BILLING, RAFIZADEH, DREW, HARTMAN, GALE, and TERASAKI 167
GAMBLE, J. R. See VADAS, MILLER, MCKENZIE, CHISM, SHEN, BOYSE, GAMBLE, and WHITELAW 10
GECZY, A. F., GECZY, C. L., and DE WECK, A. L. Histocompatibility antigens and genetic control of the immune response in guinea pigs. III. Specific inhibition of antigen-induced lymphocyte proliferation by strain-specific anti-idiotypic antibodies 226
GECZY, C. L. See GECZY, GECZY, and DE WECK 226
GERHARD, WALTER. The analysis of the monoclonal immune response to influenza virus. II. The antigenicity of the viral hemagglutinin 985
GERMAIN, RONALD N. See BURAKOFF, GERMAIN, and BENACERRAF 1609
GIBSON, D. Genetic polymorphism of mouse immunoglobulin light chains revealed by isoelectric focusing 298
GODING, JAMES W., and LAYTON, JUDITH E. Antigen-induced co-capping of IgM and IgD-like receptors on murine B cells 852
GOETZL, E. J., and AUSTEN, K. F. Structural determinants of the eosinophil chemotactic activity of the acidic tetrapeptides of eosinophil chemotactic factor of anaphylaxis 1424
GOIDL, EDMOND A., INNES, JUDITH B., and WEKSLER, MARC E. Immunological studies of aging. II. Loss of IgG and high avidity plaque-forming cells and increased suppressor cell activity in aging mice 1037
GOLDSTEIN, GIDEON. See SILVERSTONE, CANTOR, GOLDSTEIN, and BALTIMORE 543

GOLDSTEIN, JOSEPH L. See HO, BROWN, KAYDEN, and GOLDSTEIN 444
GOODMAN, GAIL W. See SULTZER and GOODMAN 821
GOODMAN, JOEL W. See LEWIS, RANKEN, NITECKI, and GOODMAN 382
GORDON, ROBERT D., MATHIESON, BONNIE J., SAMELSON, LAWRENCE E., BOYSE, EDWARD A., and SIMPSON, ELIZABETH. The effect of allogeneic presensitization on H-Y graft survival and in vitro cell-mediated responses to H-Y antigen 810
GOTSCHLICH, E. C. See FISCHETTI, GOTSCHLICH, SIVIGLIA, and ZABRISKIE 32
—. See FRASCH, PARKES, MCNELIS, and GOTSCHLICH 319
GOTTLIEB, PAUL D. See DURDA and GOTTLIEB 476
GÖTZE, OTTO. See MEDICUS, GÖTZE, and MÜLLER-EBERHARD 1076
—. See SCHREIBER, GÖTZE, and MÜLLER-EBERHARD 1062
GOULD, D. See HENSON, GOULD, and BECKER 1657
GRESSER, ION, TOVEY, MICHAEL G., BANDU, MARIE-THÉRÈSE, MAURY, CHANTAL, and BROUTY-BOYÉ, DANIÈLE. Role of interferon in the pathogenesis of virus diseases in mice as demonstrated by the use of anti-interferon serum. I. Rapid evolution of encephalomyocarditis virus infection 1305
—, TOVEY, MICHAEL G., MAURY, CHANTAL, and BANDU, MARIE-THÉRÈSE. Role of interferon in the pathogenesis of virus diseases in mice as demonstrated by the use of anti-interferon serum. II. Studies with herpes simplex, Moloney sarcoma, vesicular stomatitis, Newcastle disease, and influenza viruses 1316
GRIFFIN, FRANK M., JR., GRIFFIN, JOHANNA A., and SILVERSTEIN, SAMUEL C. Studies on the mechanism of phagocytosis. II. The interaction of macrophages with anti-immunoglobulin IgG-coated bone marrow-derived lymphocytes 788
GRIFFIN, JOHANNA A. See GRIFFIN, GRIFFIN, and SILVERSTEIN 788
GROSSI, CARLO E. See LYDYARD, GROSSI, and COOPER 79
GUERRY, DUPONT, IV, KENNA, MARGARET A., SCHREIBER, ALAN D., and COOPER, RICHARD A. Concanavalin A-mediated binding and sphering of human red blood cells by homologous monocytes 1695

H

HAKOMORI, SEN-ITIROH. See WATANABE and HAKOMORI 644
HAMBLIN, T. J. See HOUGH, EADY, HAMBLIN, STEVENSON, and STEVENSON 960
HAMILTON, JOHN, VASSALLI, JEAN-DOMINIQUE, and REICH, E. Macrophage plasminogen activator: induction by abestos is blocked by anti-inflammatory steroids 1689
HAMMARSTRÖM, LENNART. See WATERFIELD, HAMMARSTRÖM, and SMITH 562
HAMMARSTRÖM, S. See HELLSTRÖM, DILLNER, HAMMARSTRÖM, and PERLMANN 1381
HARPEL, PETER C. See BECKER and HARPEL 1
HARTMAN, GARY. See BILLING, RAFIZADEH, DREW, HARTMAN, GALE, and TERASAKI 167
HAUG, MARGARETE. See BÖSING-SCHNEIDER and HAUG 1458
HAYDEN, MICHAEL L. See SHIN, ECONOMOU, PASTERNACK, JOHNSON, and HAYDEN 1274
HELLSTRÖM, U., DILLNER, M-L., HAMMARSTRÖM, S., and PERLMANN, P. Fractionation of human T lymphocytes on wheat germ agglutinin-Sepharose 1381
HENKART, PIERRE A. See DICKLER, ARBEIT, HENKART, and SACHS 282
—. See RYAN and HENKART 768
HENSON, P. M., GOULD, D., and BECKER, E. L. Activation of stimulus-specific serine esterases (proteases) in the initiation of platelet secretion. I. Demonstration with organophosphorus inhibitors 1657
HERRMAN, HOWARD C. See HUMPHREYS, MCCUNE, CHESS, HERRMAN, MALENKA, MANN, PARHAM, SCHLOSSMAN, and STROMINGER 98
HERZENBERG, LEONARD A. See HERZENBERG, OKUMURA, CANTOR, SATO, SHEN, BOYSE, and HERZENBERG 330
—. See MURPHY, HERZENBERG, OKUMURA, HERZENBERG, and MCDEVITT 699
—. See OKUMURA, HERZENBERG, MURPHY, MCDEVITT, and HERZENBERG 685
—. See OKUMURA, METZLER, TSU, HERZENBERG, and HERZENBERG 345
—. See STOUT, WAKSAL, and HERZENBERG 54
HERZENBERG, LEONORE A., OKUMURA, KO, CANTOR, HARVEY, SATO, VICKI L., SHEN, FUNG-WIN, BOYSE, E. A., and HERZENBERG, LEONARD A. T-cell regulation of antibody responses: demonstration of allotype-specific helper T cells and their specific removal by suppressor T cells 330
—. See MURPHY, HERZENBERG, OKUMURA, HERZENBERG, and MCDEVITT 699
—. See OKUMURA, HERZENBERG, MURPHY, MCDEVITT, and HERZENBERG 685
—. See OKUMURA, METZLER, TSU, HERZENBERG, and HERZENBERG 345
HESTON, W. E., SMITH, B., and PARKS, W. P. Mouse mammary tumor virus in hybrids from strains C57BL and GR: breeding test of backcross segregants 1022
HIROKAWA, NAOYUKI. See NARUSE, FUKASAWA, HIROKAWA, OIKE, and MIYAKAWA 1347
HO, Y. K., BROWN, MICHAEL S., KAYDEN, HERBERT J., and GOLDSTEIN, JOSEPH L. Binding, internalization, and hydrolysis of low density lipoprotein in long-term lymphoid cell lines from a normal subject and a patient with

homozygous familial hypercholesterolemia 444

HOUGH, D. W., EADY, R. P., HAMBLIN, T. J., STEVENSON, F. K., and STEVENSON, G. T. Anti-idiotype sera raised against surface immunoglobulin of human neoplastic lymphocytes 960

HOYT, RICHARD. See LICHTENSTEIN, BAUER, HOYT, and WEDNER 145

HUBER, B., CANTOR, H., SHEN, F. W., and BOYSE, E. A. Independent differentiative pathways of Ly1 and Ly23 subclasses of T cells. Experimental production of mice deprived of selected T-cell subclasses 1128

HUMPHREYS, ROBERT E., MCCUNE, JOSEPH M., CHESS, LEONARD, HERRMAN, HOWARD C., MALENKA, DAVID J., MANN, DEAN L, PARHAM, PETER, SCHLOSSMAN, STUART F., and STROMINGER, JACK L. Isolation and immunologic characterization of a human, B-lymphocyte-specific, cell surface antigen 98

—. See CHESS, EVANS, HUMPHREYS, STROMINGER, AND SCHLOSSMAN

HUSBY, GUNNAR, VAN DE RIJN, IVO, ZABRISKIE, J. B., ABDIN, Z. H., and WILLIAMS, R. C., JR. Antibodies reacting with cytoplasm of subathalamic and caudate nuclei neurons in chorea and acute rheumatic fever 1094

I

IHLE, JAMES N., JOSEPH, DAVID R., and PAZMIÑO, NELSON H. Radiation leukemia in C57BL/6 mice. II. Lack of ecotropic virus expression in the majority of lymphomas 1406

–, MCEWAN, ROBERT, and BENGALI, KATHLEEN. Radiation leukemia in C57BL/6 mice. I. Lack of serological evidence for the role of endogenous ecotropic viruses in pathogenesis 1391

IKEDA, HISAMI, See KAWASHIMA, IKEDA, STOCKERT, TAKAHASHI, and OLD 193

INMAN, JOHN K. See JANEWAY, MAURER, DAILEY, and INMAN 1621

–. See REHN, INMAN, and SHEARER 1134

INNES, JUDITH B. See GOIDL, INNES, and WEKSLER 1037

IZUI, SHOZO, LAMBERT, PAUL-HENRI, and MIESCHER, PETER A. In vitro demonstration of a particular affinity of glomerular basement membrane and collagen for DNA. A possible basis for a local formation of DNA-anti-DNA complexes in systemic lupus erythematosus 428

J

JACOBS, DIANE M. See MORRISON, BETZ, and JACOBS 840

JAFFE, ERIC A., MINICK, C. RICHARD, ADELMAN, BURT, BECKER, CARL G., and NACHMAN, RALPH. Synthesis of basement membrane collagen by cultured human endothelial cells 209

JANEWAY, CHARLES A., JR., MAURER, PAUL H., DAILY, MORRIS O., and INMAN, JOHN K. The specificity of cellular immune responses in guinea pigs. II. The structure of antigenic determinants leading to T-lymphocyte stimulation 1621

–, and PAUL, WILLIAM E. The specificity of cellular immune responses in guinea pigs. III. The precision of antigen recognition by T lymphocytes 1641

JARRETT-TOTH, ESTHER, See BACH, JARRETT-TOTH, BENIKE, SHEEHY, SONDEL, and BACH 549

JENSEN, FRED C. See COOPER, JENSEN, WELSH, and OLDSTONE 970

JOHNSON, ROBERT J. See SHIN, ECONOMOU, PASTERNACK, JOHNSON, and HAYDEN 1274

JOSEPH, DAVID R. See IHLE, JOSEPH, and PAZMIÑO 1406

K

KANG, ANDREW H. See POSTLETHWAITE, SNYDERMAN, and KANG 1188

KAPLAN, EDWARD L., and WANNAMAKER, LEWIS W. Suppression of the antistreptolysin O response by cholesterol and by lipid extracts of rabbit skin 754

KAPP, JUDITH A. See PIERCE, KAPP, and BENACERRAF 371

KASHKET, EVA R. See STRAUSS, SHEEHAN, and KASHKET 1009

KAWASHIMA, KOHEI, IKEDA, HISAMI, STOCKERT, ELISABETH, TAKAHASHI, TOSHITADA, and OLD, LLOYD J. Age-related changes in cell surface antigens of preleukemic AKR thymocytes 193

KAYDEN, HERBERT J. See HO, BROWN, KAYDEN, and GOLDSTEIN 444

KAYE, SUSAN T. See ROWLEY, KÖHLER, SCHREIBER, KAYE, and LORBACH 946

KENNA, MARGARET A. See GUERRY, KENNA, SCHREIBER, and COPPER 1695

KETTMAN, JOHN R. See CAMBIER, KETTMAN, VITETTA, and UHR 293

KIELY, JEANNE-MARIE. See UNANUE, KIELY, and CALDERON 155

KLEIN, JAN. See VITETTA, POULIK, KLEIN, and UHR 179

KLINMAN, NORMAN R. See PIERCE and KLINMAN 1254

–. See PRESS, KLINMAN, and MCDEVITT 414

KÖHLER, HEINZ. See ROWLEY, KÖHLER, SCHREIBER, KAYE, and LORBACH 946

KOLB, CORNELIA, DI PAULI, RAIMUND, and WEILER, EBERHARDT. Induction of IgG in young nude mice by lipid A or thymus grafts 1031

KOSKIMIES, SAIJA, and MÄKELÄ, O. T-cell-deficient mice produce more antihapten antibod-

ies against syngeneic than against allogeneic erythrocyte conjugates 467
KRAKAUER, R. S., WALPMANN, T. A. and STROBER, W. Loss of suppressor T cells in adult NZB/NZW mice 662
KUNKEL, H. G. See FØRRE, NATVIG, and KUNKEL 897
KYNER, DAVID, ZABOS, PETER, CHRISTMAN, JUDITH, and ACS, GEORGE. Effect of sodium butyrate on lymphocyte activation 1674

L

LAMBERT, EDWARD H. See LINDSTROM, ENGEL, SEYBOLD, LENNON, and LAMBERT 739
LAMBERT, PAUL-HENRI. See IZUI, LAMBERT, and MIESCHER 428
LAYTON, JUDITH E. See GODING and LAYTON 852
LENNON, VANDA A. See LINDSTROM, EINARSON, LENNON, and SEYBOLD 726
—. See LINDSTROM, ENGEL, SEYBOLD, LENNON, and LAMBERT 739
LEVINSON, JOHN R., and MCDEVITT, HUGH O. Murine *t* factors: an association between alleles at *t* and at *H-2* 834
LEVY, ROBERT B., WAKSAL, SAMUEL D., and SHEARER, GENE M. Correlation of suppressor cell development in parental and F_1 hybrid mouse strains with the growth of a parental tumor in vitro 1363
LEWIS, GEORGE K., RANKEN, RAYMOND, NITECKI, DANUTE E., and GOODMAN, JOEL W. Murine B-cell subpopulations responsive to T-dependent and T-independent antigens 382
LICHTENSTEIN, JACK R., BAUER, EUGENE A., HOYT, RICHARD, and WEDNER, H. J. Immunologic characterization of the membrane-bound collagen in normal human fibroblasts: identification of a distinct membrane collagen 145
LILLY, FRANK. See WERNET and LILLY 266
—. See WERNET, SHAFRAN, and LILLY 654
LINDAHL, KIRSTEN FISCHER, and BACH, FRITZ H. Genetic and cellular aspects of xenogeneic mixed leukocyte culture reaction 305
LINDER, E., ANDERS, R. F., and NATVIG, J. B. Connective tissue origin of the amyloid-related protein SAA 1336
LINDSTROM, JON M., EINARSON, BRETT L., LENNON, VANDA A., and SEYBOLD, MAJORIE E. Pathological mechanisms in experimental autoimmune myasthenia gravis. I. Immunogenicity of syngeneic muscle acetylcholine receptor and quantitative extraction of receptor and antibody-receptor complexes from muscles of rats with experimental autoimmune myasthenia gravis 726
—, ENGEL, ANDREW G., SEYBOLD, MAJORIE E., LENNON, VANDA A., and LAMBERT, EDWARD H. Pathological mechanisms in experimental autoimmune myasthenia gravis. II. Passive transfer of experimental autoimmune myasthenia gravis in rats with anti-acetylcholine receptor antibodies 739
LITMAN, GARY W. See OBATA, STOCKERT, BOYSE, TUNG, and LITMAN 533
LOGIE, P. S. See MCGREGOR, LOGIE, and CARMICHAEL 627
LONG, CAROL ANN. See SCOTT and LONG 1369
LORBACH, INGRID. See ROWLEY, KÖHLER, SCHREIBER, KAYE, and LORBACH 946
LOUIE, S., CURTIS, J. E., TILL, J. E., and MCCULLOCH, E. A. Antibodies in human sera to oncornavirus-like proteins from normal or leukemic marrow cell cultures 1243
LUZZATI, ALMA L., TAUSSIG, MICHAEL J., MEO, TOMMASO, and PERNIS, BENVENUTO. Induction of an antibody response in cultures of human peripheral blood lymphocytes 573
LYDYARD, PETER M., GROSSI, CARLO E., and COOPER, MAX D. Ontogeny of B cells in the chicken. I. Sequential development of clonal diversity in the bursa 79

M

MAINES, MAHIN D. Evidence for the catabolism of polychlorinated biphenyl-induced cytochrome P-448 by microsomal heme oxygenase and the inhibition of δ-aminolevulinate dehydratase by polychorinated biphenyls 1509
MÄKELÄ, O. See KOSKIMIES and MÄKELÄ 467
MAKINODAN, TAKASHI. See ALBRIGHT and MAKINODAN 1204
MALENKA, DAVID J. See HUMPHREYS, MCCUNE, CHESS, HERRMAN, MALENKA, MANN, PARHAM, SCHLOSSMAN, and STROMINGER 98
MANN, DEAN L. See HUMPHREYS, MCCUNE, CHESS, HERRMAN, MALENKA, MANN, PARHAM, SCHLOSSMAN, and STROMINGER 98
MANNING, DEAN D., MANNNG, JUDITH K., and REED, NORMAN D. Suppression of reaginic antibody (IgE) formation in mice by treatment with anti-μ antiserum 288
MANNING, JUDITH K. See MANNING, MANNING, and REED 288
MASSON, P. L. See VAN SNICK and MASSON 1567
MATHIESEN, BONNIE J. See GORDON, MATHIESON, SAMELSON, BOYSE, and SIMPSON 810
—. See YAMAZAKI, BOYSE, MIKÉ, THALER, MATHIESON, ABBOTT, BOYSE, ZAYAS, and THOMAS 1324
MAURER, PAUL H. See JANEWAY, MAURER, DAILEY, and INMAN 1621
MAURY, CHANTAL. See GRESSER, TOVEY, BANDU, MAURY, and BROUTY-BOYÉ 1305
—. See GRESSER, TOVEY, MAURY, and BANDU 1316
MCADAM, KEITH P. W. J., and SIPE, JEAN D. Murine model for human secondary amyloidosis: genetic variability of the acute-phase serum protein SAA response to endotoxins and casein 1121

McCLAIN, DONALD, A., and EDELMAN, GERALD M. Analysis of the stimulation-inhibition paradox exhibited by lymphocytes exposed to concanavalin A 1494
McCULLOCH, E. A. See LOUIE, CURTIS, TILL, and McCULLOCH 1243
McCUNE, JOSEPH M. See HUMPHREYS, McCUNE, CHESS, HERRMAN, MALENKA, MANN, PARHAM, SCHLOSSMAN, and STROMINGER 98
McDEVITT, HUGH O. See BECHTOL and McDEVITT 123
—. See LEVINSON and McDEVITT 834
—. See MURPHY, HERZENBERG, OKUMURA, HERZENBERG, and McDEVITT 699
—. See OKUMURA, HERZENBERG, MURPHY, McDEVITT, and HERZENBERG 685
—. See PRESS, KLINMAN, and McDEVITT 414
McEWAN, ROBERT. See IHLE, McEWAN, and BENGALI 1391
McGREGOR, D. D., LOGIE, P. S., and CARMICHAEL, L. E. The mediator of cellular immunity. XII. Inhibition of activated T cells by Newcastle disease virus 627
McKENZIE, IAN F. C., and PARISH, CHRISTOPHER R. Secretion of Ia antigens by a subpopulation of T cells which are Ly-1$^+$, Ly-2$^-$, and Ia$^-$ 847
—. See VADAS, MILLER, McKENZIE, CHISM, SHEN, BOYSE, GAMBLE, and WHITELAW 10
McNELIS, R. M. See FRASCH, PARKES, McNELIS, and GOTSCHLICH 319
MEDICUS, RUDOLF G., GÖTZE, OTTO, and MÜLLER-EBERHARD, HANS J. Alternative pathway of complement: recruitment of precursor properdin by the labile C3/C5 convertase and the potentiation of the pathway 1076
MEO, TOMMASO. See LUZZATI, TAUSSIG, MEO, and PERNIS 573
METZLER, CHARLES M. See OKUMURA, METZLER, TSU, HERZENBERG, and HERZENBERG 345
MICHL, JOSEF, OHLBAUM, DIANE J., and SILVERSTEIN, SAMUEL C. 2-Deoxyglucose selectively inhibits Fc and complement receptor-mediated phagocytosis in mouse peritoneal macrophages. I. Description of the inhibitory effect 1465
—, —, and —. II. Dissociation of the inhibitory effects of 2-deoxyglucose on phagocytosis and ATP generation 1484
MIESCHER, PETER A. See IZUI, LAMBERT, and MIESCHER 428
MIKÉ, V. See YAMAZAKI, BOYSE, MIKÉ, THALER, MATHIESON, ABBOTT, BOYSE, ZAYAS, and THOMAS 1324
MILLER, J. F. A. P. See VADAS, MILLER, McKENZIE, CHISM, SHEN, BOYSE, GAMBLE, and WHITELAW 10
MILLER, R. G. See SCHILLING, PHILLIPS, and MILLER 241
MINICK, C. RICHARD. See JAFFE, MINICK, ADELMAN, BECKER, and NACHMAN 209
MIYAKAWA, YUZU. See NARUSE, FUKASWA, HIROKAWA, OIKE, MIYAKAWA 1347
MORRIS, BEDE. See ENGLISH, ADAMS, and MORRIS 586
MORRISON, DAVID C. BETZ, SALLY J., and JACOBS, DIANE M. Isolation of a lipid A bound polypeptide responsible for "LPS-initiated" mitogenesis of C3H/HeJ spleen cells 840
MÜLLER-EBERHARD, HANS J. See MEDICUS, GÖTZE, and MÜLLER-EBERHARD 1076
—. See SCHREIBER, GÖTZE, and MÜLLER-EBERHARD 1062
MUNRO, A. J. See WALDMANN, POPE, and MUNRO 1707
MURPHY, DONAL B., HERZENBERG, LEONORE A., OKUMURA, KO, HERZENBERG, LEONARD A., and McDEVITT, HUGH O. A new *I* subregion (*I-J*) marked by a locus (*Ia-4*) controlling surface determinants on suppressor T lymphocytes 699
—. See OKUMURA, HERZENBERG, MURPHY, McDEVITT, and HERZENBERG 685

N

NABHOLZ, MARKUS. See NAGY, ELLIOTT, and NABHOLZ 1545
NACHMAN, RALPH. See JAFFE, MINICK, ADELMAN, BECKER, and NACHMAN 209
NAGY, ZOLTAN, ELLIOTT, BRUCE E., and NABHOLZ, MARKUS. Specific binding of *K*- and *I*-region products of the *H-2* complex to activated thymus-derived (T) cells belonging to different Ly subclasses 1545
NARUSE, TAKUJI, FUKASAWA, TAKUTA, HIROKAWA, NAOYUKI, OIKE, SOSUKE, and MIYAKAWA, YUZU. The pathogenesis of experimental membranous glomerulonephritis induced with homologous nephritogenic tubular antigen 1347
NATVIG, J. B. See FØRRE, NATVIG, and KUNKEL 897
—. See LINDER, ANDERS, and NATVIG 1336
NEEFE, JOHN R., and SACHS, DAVID H. Specific elimination of cytotoxic effector cells. I. Adsorptive behavior of effectors and their precursors on spleen cell monolayers 996
NICHOLS, BARBARA A. Normal rabbit alveolar macrophages. I. The phagocytosis of tubular myelin 906
—. II. Their primary and secondary lysosomes as revealed by electron microscopy and cytochemistry 920
NIEDERHUBER, JOHN E. See FRELINGER, NIEDERHUBER, and SHREFFLER 1141
NITECKI, DANUTE E. See LEWIS, RANKEN, NITECKI, and GOODMAN 382
NOSSAL, G. J. V. See PIKE and NOSSAL 568

O

OBATA, YUICHI, STOCKERT, ELISABETH, BOYSE, EDWARD A., TUNG, JWU-SHENG, and LIT-

MAN, GARY W. Spontaneous autoimmunization to G_{IX} cell surface antigen in hybrid mice 533

OETTGEN, HERBERT F. See SHIKU, TAKAHASHI, BEAN, OLD, and OETTGEN 1116

—. See SHIKU, TAKAHASHI, OETTGEN, and OLD 873

OHLBAUM, DIANE J. See MICHL, OHLBAUM, and SILVERSTEIN 1465, 1484

OIKE, SOSUKE. See NARUSE, FUKASAWA, HIROKAWA, OIKE, and MIYAKAWA 1347

OKUMURA, KO, HERZENBERG, LEONORE A., MURPHY, DONAL B., MCDEVITT, HUGH O., and HERZENBERG, LEONARD A. Selective expression of *H-2* (*I*-region) loci controlling determinants on helper and suppressor T lymphocytes 685

—, METZLER, CHARLES M., TSU, THETA T., HERZENBERG, LEONARD A., and HERZENBERG, LEONORE A. Two stages of B-cell memory development with different T-cell requirements 345

—. See HERZENBERG, OKUMURA, CANTOR, SATO, SHEN, BOYSE, and HERZENBERG 330

—. See MURPHY, HERZENBERG, OKUMURA, HERZENBERG, and MCDEVITT 699

OLD, LLOYD J. See KAWASHIMA, IKEDA, STOCKERT, TAKAHASI, and OLD 193

—. See SHIKU, TAKAHASI, BEAN, OLD, and OETTGEN 1116

—. See SHIKU, TAKAHASHI, OETTGEN, and OLD 873

OLDSTONE, MICHAEL B. A. See COOPER, JENSEN, WELSH, and OLDSTONE 970

ORITZ-ORTIZ, LIBRADO, and WEIGLE, WILLIAM O. Cellular events in the induction of experimental allergic encephalomyelitis in rats 604

P

PARHAM, PETER. See HUMPHREYS, MCCUNE, CHESS, HERRMAN, MALENKA, MANN, PARHAM, SCHLOSSMAN, and STROMINGER 98

PARISH, CHRISTOPHER R. See MCKENZIE and PARISH 847

PARKES, L. See FRASCH, PARKES, MCNELIS, and GOTSCHLICH 319

PARKMAN, ROBERTSON, and ROSEN, FRED S. Identification of a subpopulation of lymphocytes in human peripheral blood cytotoxic to autologous fibroblasts 1520

PARKS, W. P. See HESTON, SMITH, and PARKS 1022

PARMELY, MICHAEL J., BEER, ALAN E., and BILLINGHAM, RUPERT E. In vitro studies on the T-lymphocyte population of human milk 358

PASTERNACK, GARY R. See SHIN, ECONOMOU, PASTERNACK, JOHNSON, and HAYDEN 1274

PAUL, WILLIAM E. See JANEWAY and PAUL 1641

—. See SCHER, SHARROW, and PAUL 507

PAUL, WILLIAM E. See SCHER, SHARROW, WISTAR, ASOFSKY, PAUL, WILLIAM E. and PAUL 494

PAZMIÑO, NELSON H. See IHLE, JOSEPH, and PAZMIÑO 1406

PERLMANN, HEDVIG. See WÅHLIN, PERLMANN, and PERLMANN 1375

PERLMANN, PETER. See HELLSTRÖM, DILLNER, HAMMARSTRÖM, and PERLMANN 1381

—. See WÅHLIN, PERLMANN, and PERLMANN 1375

PERNIS, BENVENUTO. See LUZZATI, TAUSSIG, MEO, and PERNIS 573

PHILLIPS, R. A. See SCHILLING, PHILLIPS, and MILLER 241

PIERCE, CARL W., KAPP, JUDITH A., and BENACERRAF, BARUJ. Regulation by the *H-2* gene complex of macrophage-lymphoid cell interactions in secondary antibody responses in vitro 371

PIERCE, SUSAN K., and KLINMAN, NORMAN R. Allogeneic carrier-specific enhancement of hapten-specific secondary B-cell responses 1254

PIKE, BEVERLY L., and NOSSAL, G. J. V. Requirement for persistent extracellular antigen in cultures of antigen-binding B lymphocytes 568

POPE, H. See WALDMANN, POPE, and MUNRO 1707

POSTLETHWAITE, ARNOLD E., SNYDERMAN, RALPH, and KANG, ANDREW H. The chemotactic attraction of human fibroblasts to a lymphocyte-derived factor 1188

POTTER, MICHAEL. See CANCRO and POTTER 1554

POULIK, MIROSLAV D. See VITETTA, POULIK, KLEIN, and UHR 179

PRATT, KAREN R. See FAUCI and PRATT 674

PRESS, JOAN L., KLINMAN, NORMAN R., and MCDEVITT, HUGH O. Expression of Ia antigens on hapten-specific B cells. I. Delineation of B-cell subpopulations 414

R

RAFIZADEH, BAHMAN. See BILLING, RAFIZADEH, DREW, HARTMAN, GALE, and TERASAKI 167

RANKEN, RAYMOND. See LEWIS, RANKEN, NITECKI, and GOODMAN 382

REED, NORMAN D. See MANNING, MANNING, and REED 288

REHN, TERRY G., INMAN, JOHN K., and SHEARER, GENE M. Cell-mediated lympholysis to *H-2*-matched target cells modified with a series of nitrophenyl compounds 1134

REICH, E. See HAMILTON, VASSALLI, and REICH 1689

RICH, ROBERT R. See RICH and RICH 1214

RICH, SUSAN SOLLIDAY, and RICH, ROBERT R. Regulatory mechanisms in cell-mediated immune responses. IV. Expression of a receptor for mixed lymphocyte reaction suppressor factor on activated T lymphocytes 1214

ROSEN, FRED S. See PARKMAN and ROSEN 1520
ROSENSTREICH, D. L. See WAHL and ROSENSTREICH 1175
ROWLEY, DONALD A., KÖHLER, HEINZ, SCHREIBER, HANS, KAYE, SUSAN T., and LORBACH, INGRID. Suppression by autogenous complementary idiotypes: the priority of the first response 946
RUDDY, SHAUN. See WHALEY and RUDDY 1147
RUDIKOFF, STUART, and CLAFLIN, J. LATHAM. Expression of equivalent clonotypes in BALB/c and A/J mice after immunization with phosphorylcholine 1294
RYAN, JOHN L., and HENKART, PIERRE A. Fc receptor-mediated inhibition of murine B-lymphocyte activation 768

S

SACHS, DAVID H. See DICKLER, ARBEIT, HENKART, and SACHS 282
—. See NEEFE and SACHS 996
SAMELSON, LAWRENCE E. See GORDON, MATHIESON, SAMELSON, BOYSE, and SIMPSON 810
SATO, VICKI L. See HERZENBERG, OKUMURA, CANTOR, SATO, SHEN, BOYSE, and HERZENBERG 330
SCHER, IRWIN, SHARROW, SUSAN O., and PAUL, WILLIAM E. X-linked B-lymphocyte defect in CBA/N mice. III. Abnormal development of B-lymphocyte populations defined by their densities of surface immunoglobulin 507
—, —, WISTAR, RICHARD, JR., ASOFSKY, RICHARD, and PAUL, WILLIAM E. B-lymphocyte heterogeneity: ontogenetic development and organ distribution of B-lymphocyte populations defined by their density of surface immunoglobulin 494
SCHILLING, R. M., PHILLIPS, R. A., and MILLER, R. G. Requirement for non-T cells in the generation of cytotoxic T lymphocytes in vitro. I. Use of nude mice as source of non-T cells 241
SCHLOSSMAN, STUART F. See CHESS, EVANS, HUMPHREYS, STROMINGER, and SCHLOSSMAN 113
—. See HUMPHREYS, MCCUNE, CHESS, HERRMAN, MALENKA, MANN, PARHAM, SCHLOSSMAN, and STROMINGER 98
SCHMITT-VERHULST, ANNE-MARIE, and SHEARER, GENE M. Multiple *H-2*-linked immune response gene control of *H-2D*-associated T-cell-mediated lympholysis to trinitrophenyl-modified autologous cells: *Ir*-like genes mapping to the left of *I-A* and within the *I* region 1701
SCHREIBER, ALAN D. See GUERRY, KENNA, SCHREIBER, and COOPER 1695
SCHREIBER, HANS. See ROWLEY, KÖHLER, SCHREIBER, KAYE, and LORBACH 946
SCHREIBER, ROBERT D., GÖTZE, OTTO, and MÜLLER-EBERHARD, HANS J. Alternative pathway of complement: demonstration and characterization of initiating factor and its properdin-independent function 1062
SCHREINER, GEORGE F., BRAUN, JONATHAN, and UNANUE, EMIL R. Spontaneous redistribution of surface immunoglobulin in the motile B lymphocyte 1683
SCOTT, DAVID W. Antifluorescein affinity columns. Isolation and immunocompetence of lymphocytes that bind fluoresceinated antigens in vivo or in vitro 69
—, and LONG, CAROL ANN. Role of self-carriers in the immune response and tolerance. I. B-cell unresponsiveness and cytotoxic T-cell immunity induced by haptenated syngeneic lymphoid cells 1369
SEYBOLD, MAJORIE E. See LINDSTROM, EINARSON, LENNON, and SEYBOLD 726
—. See LINDSTROM, ENGEL, SEYBOLD, LENNON, and LAMBERT 739
SHAFRAN, HOLLY. See WERNET, SHAFRAN, and LILLY 654
SHARROW, SUSAN O. see SCHER, SHARROW, and PAUL 507
—. See SCHER, SHARROW, WISTAR, ASOFSKY, and PAUL 494
SHEARER, GENE M. See LEVY, WAKSAL, and SHEARER 1363
—. See REHN, INMAN, and SHEARER 1134
—. See SCHMITT-VERHULST and SHEARER 1701
SHEEHAN, JAMES M. See STRAUSS, SHEEHAN, and KASHKET 1009
SHEEHY, MICHAEL J. See BACH, JARRETT-TOTH, BENIKE, SHEEHY, SONDEL, and BACH 549
SHEN, FUNG-WIN. See HERZENBERG, OKUMURA, CANTOR, SATO, SHEN, BOYSE, and HERZENBERG 330
—. See HUBER, CANTOR, SHEN, and BOYSE 1128
—. See VADAS, MILLER, MCKENZIE, CHISM, SHEN, BOYSE, GAMBLE, and WHITELAW 10
SHEVACH, ETHAN M. See THOMAS and SHEVACH 1263
SHIKU, HIROSHI, TAKAHASHI, TOSHITADA, BEAN, MICHAEL A., OLD, LLOYD J., and OETTGEN, HERBERT F. Ly phenotype of cytotoxic T cells from syngeneic tumor 1116
—, TAKAHASHI, TOSHITADA, OETTGEN, HERBERT F., and OLD, LLOYD J. Cell surface antigens of human malignant melanoma. II. Serological typing with immune adherence assays and definition of two new surface antigens 873
SHIN, HYUN S., ECONOMOU, JAMES S., PASTERNACK, GARY R., JOHNSON, ROBERT J., and HAYDEN, MICHAEL L. Antibody-mediated suppression of grafted lymphoma. IV. Influence of time of tumor residency in vivo and tumor size upon the effectiveness of suppression by syngeneic antibody 1274

SHREFFLER, DONALD C. See FRELINGER, NIEDERHUBER, and SHREFFLER 1141
—. See ZINKERNAGEL, DUNLOP, BLANDEN, DOHERTY, and SHREFFLER 519
SIDMAN, CHARLES L., and UNANUE, EMIL R. Control of B-lymphocyte function. I. Inactivation of mitogenesis by interactions with surface immunoglobulin and Fc-receptor molecules 882
SILVERSTEIN, SAMUEL C. See GRIFFIN, GRIFFIN, and SILVERSTEIN 788
—. See MICHL, OHLBAUM, and SILVERSTEIN 1465, 1484
SILVERSTONE, ALLEN E., CANTOR, HARVEY, GOLDSTEIN, GIDEON, and BALTIMORE, DAVID. Terminal deoxynucleotidyl transferase is found in prothymocytes 543
SIMPSON, ELIZABETH. See GORDON, MATHIESON, SAMELSON, BOYSE, and SIMPSON 810
SIPE, JEAN D. See MCADAM and SIPE 1121
SIVIGLIA, G., See FISCHETTI, GOTSCHLICH, SIVIGLIA, and ZABRISKIE 32
SMITH, B. See HESTON, SMITH, and PARKS 1022
SMITH, EDVARD. See WATERFIELD, HAMMARSTRÖM, and SMITH 562
SNYDERMAN, RALPH. See POSTLETHWAITE, SYNDERMAN, and KANG 1188
SONDEL, PAUL M. See BACH, JARRETT-TOTH, BENIKE, SHEEHY, SONDEL, and BACH 549
SPRENT, J., and VON BOEHMER, H. Helper function of T cells depleted of alloantigen-reactive lymphocytes by filtration through irradiated F_1 hybrid recipients. I. Failure to collaborate with allogeneic B cells in a secondary response to sheep erythrocytes measured in vivo 617
STAMPER, HUGH B., and WOODRUFF, JUDITH J. Lymphocyte homing into lymph nodes: in vitro demonstration of the selective affinity of recirculating lymphocytes for high-endothelial venules 828
STEVENSEN, F. K. See HOUGH, EADY, HAMBLIN, STEVENSON, and STEVENSON 960
STEVENSON, G. T. See HOUGH, EADY, HAMBLIN, STEVENSON, and STEVENSON 960
STOBO, J. D. See WHISLER and STOBO 398
STOCKERT, ELISABETH. See KAWASHIMA IKEDA, STOCKERT, TAKAHASHI, and OLD 193
—. See OBATA, STOCKERT, BOYSE, TUNG, and LITMAN 533
STOUT, ROBERT D., WAKSAL, SAMUEL D., and HERZENBERG, LEONARD A. The Fc receptor on thymus-derived lymphocytes. III. Mixed lymphocyte reactivity and cell-mediated lympholytic activity of Fc^- and Fc^+ T lymphocytes 54
STRAUSS, PHYLLIS R., SHEEHAN, JAMES M., and KASHKET, EVA R. Membrane transport by murine lymphocytes. I. A rapid sampling technique as applied to the adenosine and thymidine systems 1009
STROBER, W. See KRAKAUER, WALDMANN, and STROBER 662
STROMINGER, JACK L. See CHESS, EVANS, HUMPHREYS, STROMINGER, and SCHLOSSMAN 113
—. See HUMPHREYS, MCCUNE, CHESS, HERRMAN, MALENKA, MANN, PARHAM, SCHLOSSMAN, and STROMINGER 98
SULTZER, BARNET M., and GOODMAN, GAIL W. Endotoxin protein: a B-cell mitogen and polyclonal activator of C3H/HeJ lymphocytes 821

T

TADA, TOMIO, TANIGUCHI, MASARU, and DAVID, CHELLA S. Properties of the antigen-specific suppressive T-cell factor in the regulation of antibody response of the mouse. IV. Special subregion assignment of the gene(s) that codes for the suppressive T-cell factor in the *H-2* histocompatibility complex 713
—. See TANIGUCHI, TADA, and TOKUHISA 20
TAKAHASHI, TOSHITADA. See KAWASHIMA, IKEDA, STOCKERT, TAKAHASHI, and OLD 193
—. See SHIKU, TAKAHASHI, BEAN, OLD, and OETTGEN 1116
—. See SHIKU, TAKAHASHI, OETTGEN, and OLD 873
TANIGUCHI, MASARU, TADA, TOMIO, and TOKUHISA, TAKESHI. Properties of the antigen-specific suppressive T-cell factor in the regulation of antibody response of the mouse. III. Dual gene control of the T-cell-mediated suppression of the antibody response 20
—. See TADA, TANAGUCHI, and DAVID 713
TAUSSIG, MICHAEL J. See LUZZATI, TAUSSIG, MEO, and PERNIS 573
TAYLOR, B. A. See BEREK, TAYLOR, and EICHMANN 1164
TERASAKI, PAUL. See BILLING, RAFIZADEH, DREW, HARTMAN, GALE, and TERASAKI 167
THALER, H. T. See YAMAZAKI, BOYSE, MIKÉ, THALER, MATHIESON, ABBOTT, BOYSE, ZAYAS, and THOMAS 1324
THOMAS, DAVID W., and SHEVACH, ETHAN M. Nature of the antigenic complex recognized by T lymphocytes. I. Analysis with an in vitro primary response to soluble protein antigen 1263
THOMAS, L. See YAMAZAKI, BOYSE, MIKÉ, THALER, MATHIESON, ABBOTT, BOYSE, ZAYAS, and THOMAS 1324
THOMAS, W. R., ASHERSON, G. L., and WATKINS, MADELEINE C. Reaginic antibody produced in mice with contact sensitivity 1386
TILL, J. E. See LOUIE, CURTIS, TILL, and MCCULLOCH 1243
TOKUHISA, TAKESHI. See TANIGUCHI, TADA, and TOKUHISA 20
TOVEY, MICHAEL G. See GRESSER, TOVEY, BANDU, MAURY and BROUTY-BOYÉ 1305
—. See GRESSER, TOVEY, MAURY, and BANDU 1316

TSU, THETA T. See OKUMURA, METZLER, TSU, HERZENBERG, and HERZENBERG 345
TUNG, JWU-SHENG. See OBATA, STOCKERT, BOYSE, TUNG, and LITMAN 533
TWAROG, FRANK J. See ZEIGER, TWAROG, and COLTEN 1049

U

UHR, JONATHAN W. See CAMBIER, KETTMAN, VITETTA, and UHR 293
—. See VITETTA, POULIK, KLEIN, and UHR 179
UNANUE, EMIL R., KIELY, JEANNE-MARIE, and CALDERON, JESUS. The modulation of lymphocyte functions by molecules secreted by macrophages. II. Conditions leading to increased secretion 155
—. See SCHREINER, BRAUN, and UNANUE 1683
—. See SIDMAN UNANUE 882

V

VADAS, M. A., MILLER, J. F. A. P., MCKENZIE, I. F. C., CHISM, S. E., SHEN, F-W., BOYSE, E. A., GAMBLE, J. R., and WHITELAW, A. M. Ly and Ia antigen phenotypes of T cells involved in delayed-type hypersensitivity and in suppression 10
VAN DE RIJN, IVO. See HUSBY, VAN DE RIJN, ZABRISKIE, ABDIN, and WILLIAMS 1094
VAN EPPS, DENNIS, E., and WILLIAMS, RALPH C., JR. Suppression of leukocyte chemotaxis by human IgA myeloma components 1227
VAN SNICK, J. L., and MASSON, P. L. The binding of human lactoferrin to mouse peritoneal cells 1567
VASSALLI, JEAN-DOMINIQUE. See HAMILTON, VASSALLI, and REICH 1689
VISCHER, T. L., BRETZ, U., and BAGGIOLINI, M. In vitro stimulation of lymphocytes by neutral proteinases from human polymorphonuclear leukocyte granule 863
VITETTA, ELLEN S., POULIK, MIROSLAV D., KLEIN, JAN, and UHR, JONATHAN W. Beta 2-microglobulin is selectively associated with H-2 and TL alloantigens on murine lymphoid cells 179
—. See CAMBIER, KETTMAN, VITETTA, and UHR 293
VON BOEHMER, H. See SPRENT and VON BOEHMER 617

W

WAHL, S. M., and ROSENSTREICH, D. L. Role of B lymphocytes in cell-mediated immunity. I. Requirement for T cells or T-cell products for antigen-induced B-cell activation 1175
WÅHLIN, BIRGITTA, PERLMANN, HEDVIG, and PERLMANN, PETER. Analysis by a plaque assay of IgG- or IgM-dependent cytolytic lymphocytes in human blood 1375
WAKSAL, SAMUEL D. See LEVY, WAKSAL, and SHEARER 1363
—. See STOUT, WAKSAL, and HERZENBERG 54
WALDMANN, H., POPE, H., and MUNRO, A. J. Cooperation across the histocompatibility barrier: *H-2*^{d} T cells primed to antigen in an *H-2*^{d} environment can cooperate with *H-2*^{k} B cells 1707
WALDMANN, T. A. See KRAKAUER, WALDMANN, and STROBER 662
WALKER, M. See FAANES, WALKER, and CHOI 1284
WALTENBAUGH, CARL. See DEBRÉ, WALTENBAUGH, DORF, and BENACERRAF 272, 277
WANNAMAKER, LEWIS W. See KAPLAN and WANNAMAKER 754
WATANABE, KIYOHIRO, and HAKOMORI, SEN-ITIROH. Status of blood group carbohydrate chains in ontogenesis and in oncogenesis 644
WATERFIELD, J. DOUGLAS, HAMMARSTRÖM, LENNART, and SMITH, EDVARD. The effect of membrane stabilizing agents on induction of the immune response. I. Effect of lymphocyte activation in mixed lymphocyte reactions 562
WATKINS, MADELEINE C. See THOMAS, ASHERSON, and WATKINS 1386
WEDNER, H. J. See LICHTENSTEIN, BAUER, HOYT, and WEDNER 145
WEIGLE, WILLIAM O. See ORTIZ-ORTIZ and WEIGLE 604
WEILER, EBERHARDT. See KOLB, DI PAULI, and WEILER 1031
WEKSLER, MARC E. See GOIDL, INNES, and WEKSLER 1037
WELSH, RAYMOND M., JR. See COOPER, JENSEN, WELSH, and OLDSTONE 970
WERNET, DOROTHEE, and LILLY, FRANK. Genetic regulation of the antibody response to *H-2D*^{b} alloantigens in mice. II. Tolerance to non-*H-2* determinants abolishes the antibody response to *H-2D*^{b} in B.10.A(5R) mice 266
—, SHAFRAN, HOLLY, and LILLY, FRANK. Genetic regulation of the antibody response to *H-2D*^{b} alloantigens in mice. III. Inhibition of the IgG response to noncongenic cells by preimmunization with congenic cells 654
WHALEY, KEITH, and RUDDY, SHAUN. Modulation of the alternative complement pathway by β1H globulin 1147
WHISLER, R. L., and STOBO, J. D. Heterogeneity of murine regulatory T cells. I. Subpopulations of amplifier and suppressor T cells 398
WHITELAW, A. M. See VADAS, MILLER, MCKENZIE, CHISM, SHEN, BOYSE, GAMBLE, and WHITELAW 10
WIGZELL, HANS. See BINZ and WIGZELL 1438
WILLIAMS, RALPH C., JR. See HUSBY, VAN DE RIJN, ZABRISKIE, ABDIN, and WILLIAMS 1094
—. See VAN EPPS and WILLIAMS 1227
WISTAR, RICHARD, JR. See SCHER, SHARROW, WISTAR, ASOFSKY, and PAUL 494
WOODRUFF, JUDITH J. See STAMPER and WOODRUFF 828

Y

YAMAZAKI, K., BOYSE, EDWARD A., MIKÉ, V., THALER, H. T., MATHIESON, B. J., ABBOTT, J., BOYSE, J., ZAYAS, Z. A., and THOMAS, L. Control of mating preferences in mice by genes in the major histocompatibility complex 1324

Z

ZABOS, PETER. See KYNER, ZABOS, CHRISTMAN, and ACS 1674
ZABRISKIE, J. B. See FISCHETTI, GOTSCHLICH, SIVIGLIA, and ZABRISKIE 32
—. See HUSBY, VAN DE RIJN, ZABRISKIE, ABDIN, and WILLIAMS 1094
ZAYAS, Z. A. See YAMAZAKI, BOYSE, MIKÉ, THALER, MATHIESON, ABBOTT, BOYSE, ZAYAS, and THOMAS 1324
ZEIGER, ROBERT S., TWAROG, FRANK J., and COLTEN, HARVEY R. Histaminase release from human granulocytes 1049
ZINKERNAGEL, ROLF, M. *H-2* restriction of virus-specific T-cell-mediated effector functions in vivo. II. Adoptive transfer of delayed-type hypersensitivity to murine lymphocytic choriomeningitis virus is restricted by the *K* and *D* region of *H-2* 776
—. *H-2* restriction of virus-specific cytotoxicity across the *H-2* barrier. Separate effector T-cell specificities are associated with self-*H-2* and with tolerated allogeneic *H-2* chimeras 933
—, DUNLOP, MALCOLM B. C., BLANDEN, ROBERT V., DOHERTY, PETER C., and SHREFFLER, DONALD C. *H-2* compatibility requirement for virus-specific T-cell-mediated cytolysis. Evaluation of the role of *H-2I* region and non-*H-2* genes in regulating immune response 519

INDEX TO SUBJECTS

A

Acetylcholine, anti-, receptor antibodies, passive transfer of autoimmune myasthenia gravis, 739
– receptor, antibody-receptor complex, muscles in autoimmune myasthenia gravis, 726
Activator, macrophage plasminogen, induction by asbestos blocked by anti-inflammatory steroids, 1689
Adenosine and thymidine, membrane transport, lymphocytes, 1009
Adsorption, cytotoxic effector cells, 996
Age and cell surface antigens, preleukemic AKR thymocytes, 193
–, loss of IgG and high avidity plaque-forming cells, increased suppressor cell activity, 1037
Agglutinin, wheat germ, and Sepharose fractionation of human T lymphocytes, 1381
Albumin complex to SAA, antiserum to serum amyloid A protein, 1679
Alleles, *t* and *H-2* association, 834
Allergic encephalomyelitis, cellular events in induction of, 604
Alloantigen-reactive lymphocytes, helper function of T cells depleted of, by in vivo filtration, 617
Alloantigens, *H-2* and TL, β2-microglobulin association, lymphoid cells, 179
–, *H-2D*^{b}, genetic control of antibody response to, 266
–, *H-2D*^{b}, genetic regulation of antibody response to, inhibition of IgG response to noncongenic cells, 654
Allogeneic B cells, failure to collaborate with T cells depleted of alloantigen-reactive lymphocytes, 617
– carrier-specific enhancement, hapten-specific secondary B cell responses, 1254
– presensitization and H-Y graft survival, cell-mediated response to H-Y antigen, 810
– and syngeneic erythrocyte conjugates, antihapten antibody production, T cell deficiency, 467
Allotype-specific helper T cells, removal by suppressor T cells, 330
Alveolar macrophages, phagocytosis of tubular myelin, 906
– macrophages, primary and secondary lysosomes, 920
δ-Aminolevulinate dehydratase, inhibition by polychlorinated biphenyls, 1509
Amplifier and suppressor T cells, murine subpopulations, 398
Amyloid protein SAA antiserum to, albumin complex, 1679
Amyloidosis, connective tissue origin of protein SAA, 1336
–, human, murine model, genetic variability of serum protein SAA response to endotoxins and casein, 1121
Anaphylaxis, eosinophil chemotactic factor, structural determinants of acidic tetrapeptides, 1424
Antibodies, anti-acetylcholine receptor, passive transfer of autoimmune myasthenia gravis, 739
–, anti-idiotypic, specific inhibition of antigen-induced lymphocyte proliferation, 226
–, group-specific and type-specific, protection against Group B meningococcal disease, chick embryo, 319
– to oncornavirus-like proteins, leukemic marrow cells, 1243
Antibody, antihapten, production against syngeneic and allogeneic erythrocyte conjugates, T cell deficiency, 467
– to cytoplasm of subthalamic and caudate nuclei neurons, in chorea and acute rheumatic fever, 1094
– formation, reaginic, suppression with anti-μ antiserum, 288
–, reaginic, contact sensitivity, 1386
– response, gene control of suppression of, antigen-specific T cell factor, 20
– response to *H-2D*^{b} alloantigens, genetic control, 266
– response to *H-2D*^{b} alloantigens, genetic regulation of, inhibition of IgG response to noncongenic cells, 654
– response, induction of in human blood lymphocytes, 573
– response to polypeptide immunization, tetraparental mice, 123
– response, T cell regulation, allotype-specific helper T cells, removal by suppressor T cells, 330
–, secondary responses, regulation by *H-2* gene complex of macrophage-lymphoid cell interactions, 371
–, syngeneic, suppression of grafted lymphoma, role of time and tumor size, 1274
Antibody-receptor complex, and syngeneic muscle acetylcholine receptor, autoimmune myasthenia gravis, 726
Antifluorescein affinity columns, isolation of

immunocompetent lymphocytes, 69
Antigen, cell surface, human B lymphocyte-specific, 98
– determinants, T lymphocyte stimulation, 1621
–, extracellular, requirement in cultures of antigen-binding B lymphocytes, 568
–, G_{IX} cell surface, autoimmunization, 533
–, H-Y, cell-mediated responses, effect of allogeneic sensitization, 810
–, Ia, and Fc receptors, T lymphocytes, 282
– induction, B cell activation, role of T cells, 1175
– induction, cocapping of IgM and IgD-like receptors, B cells, 852
– phenotypes, Ly and Ia, T cells, delayed-type hypersensitivity and suppression, 10
– primed *H-2*^{d} T cells, cooperation with *H-2*^{k} cells, histocompatibility barrier, 1707
– recognition by T lymphocytes, 1641
–, tubular, nephritogenic, induction of membranous glomerulonephritis, 1347
Antigen-binding cell populations, variation and control of, 259
– receptors, idiotypic, autoimmunization, transplantation tolerance, 1438
Antigenicity of hemagglutinin, monoclonal immune response to influenza virus, 985
Antigens, cell surface, preleukemic AKR thymocytes, age-related changes, 193
–, fluoresceinated, isolated of immunocompetent lymphocytes, 69
–, histocompatibility, genetic control of immune response, specific inhibition of lymphocyte proliferation by anti-idiotypic antibodies, 226
–, HLA-D region, primed LD typing, 549
–, human B lymphocytes, lymphocytic and myelocytic leukemia cells, 167
–, Ia, expression of, on hapten-specific B cells, 414
–, Ia, secretion by T cell subpopulation, 847
–, Ly-3, mouse thymocytes, immune precipitation and molecular weight characterization, 476
–, soluble protein, T lymphocyte primary response, 1263
–, surface, human malignant melanoma, serological typing with immune adherence assays, 873
–, T-dependent and T-independent, murine B cell subpopulations responsive to, 382
Antigen-specific suppressive T cell factor, gene control of antibody response, 20
– suppressor T cell factor, subregion gene assignment in *H-2* histocompatibility complex, 713
Antihapten antibody production against syngeneic and allogeneic erythrocyte conjugates, T cell deficiency, 467
Anti-idiotype serum, against surface immunoglobulin, human neoplastic lymphocytes, 960
Anti-immunoglobulin IgG-coated B lymphocytes, interaction with macrophages, 788
Anti-interferon serum, pathogenesis of virus diseases, 1305, 1316
Antiphagocytic and type-specific molecules, streptococcal M protein extraction by nonionic detergent, 32
Antiserum, amyloid A protein, albumin complex, 1679
–, anti-μ, suppression of reaginic antibody formation, 288
Antistreptolysin O suppression by cholesterol and skin lipids, 754
Asbestos induction of macrophage plasminogen activator, effect of anti-inflammatory steroids, 1689
Assays, immune adherence, serological typing with, human malignant melanoma surface antigens, 873
–, plaque-forming cell, human B lymphocyte polyclonal activation, 674
ATP generation and phagocytosis, inhibition by 2-deoxyglucose, peritoneal macrophages, 1484
Autoimmune myasthenia gravis, passive transfer with anti-acetylcholine receptor antibodies, 739
– myasthenia gravis, syngeneic muscle acetylcholine receptor and antibody-receptor complex, 726
Autoimmunization against idiotypic antigen-binding receptors, transplantation tolerance, 1438
– to G_{IX} cell surface antigen, 533

B

B cell activation, antigen-induced, role of T cells, 1175
– cell memory development, T cell requirements, 345
– cell mitogen, polyclonal activator of lymphocytes, endotoxin protein, 821
– cell subpopulations, murine response to T-dependent and T-independent antigens, 382
– cell tolerance induction, neonatal and adult spleen cell susceptibility to, 293
– cells, allogeneic, failure to collaborate with T cells depleted of alloantigen-reactive lymphocytes, 617
– cells, antigen-induced cocapping of IgM and IgD-like receptors, 852
– cells, hapten-specific, expression of Ia antigens, 414
– cells, ontogeny of, clonal diversity in chicken bursa, 79
– cells, secondary, hapten-specific responses, allogeneic carrier-specific enhancement, 1254
– lymphocyte activation, Fc receptor-mediated inhibition, 768
– lymphocyte antigens, human, lymphocytic and myelocytic leukemia cells, 167

– lymphocyte function, mitogenesis inactivation, interactions with surface immunoglobulin and Fc receptors, 882
– lymphocyte X-linked defect, CBA/N mice, surface immunoglobulin density, 507
– lymphocytes, antigen-binding, requirement for extracellular antigen in cultures of, 568
– lymphocytes, anti-immunoglobulin IgG-coated, interaction with macrophages, 788
– lymphocytes, human, Ia-like antiserum, inhibition of antibody-dependent cytotoxicity and immunoglobulin synthesis, 113
– lymphocytes, human, polyclonal activation, direct plaque-forming cell assay, 674
– lymphocytes, human, specific cell surface antigen, 98
– lymphocytes, motile, surface immunoglobulin redistribution, 1683
– lymphocytes, surface immunoglobulin density, ontogenetic development and organ distribution, 494
Backcross segregants, breeding test, mammary tumor virus, 1022
Barrier, *H-2*, restriction of virus-specific cytotoxicity, chimeras, 933
–, histocompatibility, cooperation between *H-2*^{d} T cells primed to antigen and *H-2*^{k} cells, 1707
Basement membrane collagen, synthesis by human endothelial cells, 209
– membrane, glomerular, interaction with collagen and DNA, systemic lupus erythematosus, 428
Binding and sphering of concanavalin A-coated human red blood cells by monocytes, 1695
Blood group carbohydrate chains, ontogenesis and oncogenesis, 644
–, human, lymphocyte subpopulation cytotoxic to autologous fibroblasts, 1520
–, human, plaque assay for IgG- or IgM-dependent cytolytic lymphocytes, 1375
– lymphocytes, human, induction of antibody response, 573
Bone marrow cells, leukemia, antibodies to oncornavirus-like proteins from, 1243
– marrow stem cells, spleen-colonizing, aging mice, decreased growth potential, 1204
Breeding test of backcross segregants, mammary tumor virus, 1022
Bursa, chicken, clonal diversity of B cells, 79
Butyrate, sodium, effect on lymphocyte activation, 1674

C

Capping, antigen-induced, IgM and IgD-like receptors, B cells, 852
Carbohydrate chains, blood groups, ontogenesis and oncogenesis, 644
–, Group A streptococcal, myeloma protein S117, multiple chromosomal loci for V_H genes, 1164
Carrier-specific enhancement, allogeneic, hapten-specific secondary B cell responses, 1254
Casein, serum protein SAA response, genetic variability, amyloidosis, 1121
Caudate nuclei and subthalamic neurons, reactive antibodies, in chorea and acute rheumatic fever, 1094
Cell populations, antigen-binding, variation and control of, 259
– substratum, adherent, role in plasmacytoma growth, 1554
– surface antigen, G_{IX}, autoimmunization, 533
– surface antigen, human B lymphocyte specific, 98
– surface antigens, human malignant melanoma, serological typing with immune adherence assays, 873
– surface antigens, preleukemic AKR thymocytes, age-related changes, 193
Cell-mediated immunity, role of T cells in antigen-induced B cell activation, 1175
– lympholysis, Fc receptor of T lymphocytes, 54
– lympholysis, *H-2* matched target cells, modification by nitrophenyl compounds, 1134
– responses to H-Y antigen, effect of allogeneic sensitization, 810
Cells, B, antigen-induced cocapping of IgM and IgD-like receptors, 852
–, B, hapten-specific, expression of Ia antigens, 414
–, B, memory development, T cell requirements, 345
–, B, mitogen and polyclonal activator of lymphocytes, endotoxin protein, 821
–, B, ontogeny of, clonal diversity in chicken bursa, 79
–, B, secondary, hapten-specific responses, allogeneic carrier-specific enhancement, 1254
–, B, subpopulations, murine, response to T-dependent and T-independent antigens, 382
–, endothelial, human, basement membrane collagen synthesis, 209
–, leukemia, lymphocytic and myelocytic, human B lymphocyte antigens, 167
–, lymphoid, haptenated syngeneic, role of self-carriers in immune response and tolerance, 1369
–, lymphoid, low density lipoprotein metabolism, familial hypercholesterolemia, 444
–, lymphoid, and macrophage interactions, regulation by *H-2* gene complex, secondary antibody responses, 371
–, lymphoid, β2-microglobulin association with *H-2* and TL alloantigens, 179
–, lymphoid, sheep, immunoglobulin synthesis and secretion, primary response to salmonella lipopolysaccharide, 586
–, marrow, leukemia, antibodies to oncornavirus-like proteins from, 1243

–, noncongenic, inhibition of IgG response to *H-2D*^{b} by preimmunization, 654
–, non-T, role in generation of cytotoxic T lymphocytes, 241
–, nude mouse, induction and abrogation of unresponsiveness, 1458
–, peritoneal, mouse, binding of human lactoferrin, 1567
–, plaque-forming, high avidity, and IgG, loss of in aging mice, 1037
–, spleen, cytotoxicity, adsorptive behavior of effectors, 996
–, spleen, lipid A bound polypeptide, LPS-initiated mitogenesis, 840
–, spleen, neonatal and adult susceptibility to induction of B cell tolerance, 293
–, stem, bone marrow, spleen-colonizing, aging mice, decreased growth potential, 1204
–, suppressor, correlation in parental and F_1 hybrid mouse strains, anti-tumor response, 1363
–, T, amplifier and suppressor, murine subpopulations, 398
–, T, antigen-specific suppressive factor, gene control of antibody response, 20
–, T, cytotoxic, Ly phenotype for syngeneic tumor, 1116
–, T, deficiency, antihapten antibody production against syngeneic and allogeneic erythrocyte conjugates, 467
–, T, depletion of alloantigen-reactive lymphocytes by in vivo filtration, helper function of, 617
–, T, *H-2*^{d} primed to antigen, cooperation with *H-2*^{k} cells, histocompatibility barrier, 1707
–, T, independent pathways of Ly1 and Ly23 subclasses, 1128
–, T, inhibition by Newcastle disease virus, 627
–, T, Ly and Ia antigens, delayed-type hypersensitivity and suppression, 10
–, T, Ly subclasses, binding of *K*- and *I*-region products of *H-2* complex, 1545
–, T, regulation of antibody responses, allotype-specific helper T cells, removal by suppressor T cells, 330
–, T, requirements for B cell memory development, 345
–, T, role in antigen-induced B cell activation, 1175
–, T, subpopulation secretion of Ia antigen, 847
–, T, suppressor factor, antigen-specific, subregion gene assignment in *H-2* histocompatibility complex, 713
–, T, suppressor, loss of in adult NZB/NZW mice, 662
–, T, virus-specific cytolysis, *H-2* compatibility, 519
–, target, *H-2* incompatible, trinitrophenyl-derivatized, cytolysis of by T lymphocytes, 1609
–, trinitrophenyl-modified autologous, *H-2*-linked immune response gene control of *H-2D*-associated T-cell-mediated lympholysis, 1701
Cellular aspects, xenogeneic mixed leukocyte culture reaction, 305
– distribution, peritoneal macrophage 5′-nucleotidase, 1596
– events, induction of experimental allergic encephalomyelitis, 604
– immune responses, antigen recognition by T lymphocytes, 1641
– immune responses, structure of antigenic determinants leading to T lymphocyte stimulation, 1621
– immunity mediator, T cell inhibition by Newcastle disease virus, 627
Chains, heavy Ig, variable region subgroups, serological detection, 897
–, light, immunoglobulin, genetic polymorphism, 298
Chemotaxis, eosinophil factor of anaphylaxis, structural determinants of acidic tetrapeptides, 1424
–, fibroblasts, lymphocyte-derived factor, 1188
–, leukocytes, suppression of by human IgA myeloma components, 1227
Chick embryo, group-specific and type-specific protection against Group B meningococcal disease, 319
–, hemolytic complement and major histocompatibility complex, 555
Chimeras, *H-2* restriction of virus-specific cytotoxicity across barrier, 933
Chlorpromazine, induction of immune response, effect of lymphocyte activation, 562
Cholesterol and skin lipids, suppression of antistreptolysin O response, 754
Chorea, antibodies reactive to subthalamic and caudate nuclei neurons, 1094
Chromosome, multiple, loci for V_H genes, myeloma protein S117, Group A streptococcal carbohydrate, 1164
Clone generation, chicken bursa, ontogeny of B cells, 79
Clonotypes, equivalent, phosphorylcholine immunization, 1294
Coagulation factors and complement system, role in macrophage spreading, 1531
Collagen, basement membrane, synthesis by human endothelial cells, 209
– interaction with DNA and glomerular basement membrane, systemic lupus erythematosus, 428
–, membrane, human fibroblasts, immunologic characterization, 145
Columns, antifluorescein affinity, isolation of immunocompetent lymphocytes, 69
Complement alternate pathway, initiating factor, properdin-independent function, 1062
– alternate pathway, modulation by β1H globulin, 1147
– alternate pathway, precursor properdin recruitment by labile C3/C5 convertase, 1076

– *C2* and *Bf*, human, genetic linkage between, 1111
–, hemolytic, and major histocompatibility complex, chicken, 555
– lysis of RNA tumor viruses, human serum, 970
– receptor-mediated phagocytosis, peritoneal macrophages, inhibition by 2-deoxyglucose, 1465, 1484
– system and coagulation factors, role in macrophage spreading, 1531
Complex, *H-2* gene, regulation of macrophage-lymphoid cell interactions, secondary antibody responses, 371
–, *H-2*, *K*- and *I*-region products, binding to T cells of different Ly subclasses, 1545
–, major histocompatibility, gene control of mating preferences, 1324
–, major histocompatibility, and serum hemolytic complement, chicken, 555
–, soluble protein antigen, T lymphocyte primary response, 1263
Concanavalin A-coated red blood cells, binding and sphering by monocytes, 1695
– stimulation and inhibition of lymphocytes, 1494
– A, synergy between precursor and mature T lymphocytes in response to, 456
– A-reactive cells, gene mapping of Ia determinants, *I-J* subregion of *H-2* complex, 1141
Conjugates, erythrocytes, allogeneic and syngeneic, antihapten antibody production, T cell deficiency, 467
Connective tissue origin, amyloid-related protein SAA, 1336
Contact sensitivity, reaginic antibody, 1386
Convertase, labile C3/C5, recruitment of precursor properdin, complement alternate pathway, 1076
Copolymer (Glu,Tyr), immune suppression, cyclophosphamide-induced response, 277
– (Glu,Tyr), immune suppression, mapping of *H-2* complex complementing genes, 272
CORRECTION 859
Cyclophosphamide, induced response to copolymer (Glu,Tyr), genetic control of immune suppression, 277
Cytochemistry, alveolar macrophage lysosomes, 920
Cytochrome P-448, polychlorinated biphenyl-induced, catabolism by microsomal heme oxygenase, 1509
Cytolysis, T cell-mediated, virus-specific, *H-2* compatibility, 519
–, trinitrophenyl-derivatized *H-2* incompatible target cells by T lymphocytes, 1609
Cytoplasm antibody, subthalamic and caudate nuclei neurons, in chorea and acute rheumatic fever, 1094
Cytotoxicity, antibody-dependent, inhibition by human B cell antiserum, 113
–, autologous fibroblasts, lymphocyte subpopulation in human blood, 1520
–, lymphocyte-mediated, isoantiserum augmentation, 1284
–, spleen cells, adsorptive behavior of effectors, 996
–, T cells, Ly phenotype for syngeneic tumor, 1116
–, T lymphocytes, role of non-T cells, 241
–, virus-specific, *H-2* restriction of across barrier, chimeras, 933

D

D and K region, *H-2*, restriction of transfer of delayed-type hypersensitivity to lymphocytic choriomeningitis virus, 776
Density, surface immunoglobulins, B lymphocytes, ontogenetic development and organ distribution, 494
–, surface immunoglobulins, B lymphocytes, X-linked defect, 507
2-Deoxyglucose inhibition of Fc and complement receptor-mediated phagocytosis, peritoneal macrophages, 1465
– inhibition of phagocytosis and ATP generation, peritoneal macrophages, 1484
Deoxynucleotidyl transferase, terminal, prothymocytes, 543
Detergent, nonionic, extraction of streptococcal M protein, antiphagocytic and type-specific molecules, 32
Diseases, virus, role of interferon, 1305,1316
DNA interaction with collagen and glomerular basement membrane, systemic lupus erythematosus, 428

E

Ecotropic virus, endogenous, role in pathogenesis of radiation leukemia, lack of serological evidence, 1391
– virus expression, lack of in lymphomas, radiation leukemia, 1406
Electron microscopy, alveolar macrophage lysosomes, 920
Embryo, chick, group-specific and type-specific protection against Group B meningococcal disease, 319
Encephalomyelitis, allergic, cellular events in induction of, 604
Encephalomyocarditis, role of interferon, 1305
Endocytosis, effect on 5′-nucleotidase, peritoneal macrophages, 1596
Endothelial cells, human, basement membrane collagen synthesis, 209
Endothelium, human vascular, α_2-macroglobulin, 1
Endotoxin protein, B cell mitogen, polyclonal activator of lymphocytes, 821
–, serum protein SAA response, genetic variability, amyloidosis, 1121
Eosinophil chemotactic factor of anaphylaxis, structural determinants of acidic tetrapeptides, 1424
Erythrocyte conjugates, allogeneic and synge-

neic, antihapten antibody production, T cell deficiency, 467
Erythrocytes, man, concanavalin A-mediated binding and sphering by monocytes, 1695
Esterases, serine, activation of in platelet secretion, organophosphorus inhibition, 1657

F

Factor B and C2, human, genetic linkage between, 1111
–, coagulation, and complement system, role in macrophage spreading, 1531
–, eosinophil chemotactic, of anaphylaxis, structural determinants of acidic tetrapeptides, 1424
–, initiating, properdin-independent function, complement alternate pathway, 1062
–, lymphocyte-derived, human fibroblast chemotaxis, 1188
–, suppressor, mixed lymphocyte reaction, T lymphocyte receptor for, 1214
–, suppressor, T cells, antigen-specific, subregion gene assignment in *H-2* histocompatibility complex, 713
–, *t*, association with alleles at *H-2*, 834
–, T cell, antigen-specific, gene control of suppression of antibody response, 20
Fc and complement receptor-mediated phagocytosis, peritoneal macrophages, inhibition by 2-deoxyglucose, 1465, 1484
– receptor and Ia antigen, T lymphocytes, 282
– receptor-mediated inhibition of B lymphocyte activation, 768
– receptor and surface immunoglobulins, mitogenesis inactivation by interactions with, B lymphocytes, 882
– receptor, T lymphocytes, mixed reaction and cell-mediated lympholysis, 54
Fibroblasts, autologous, lymphocyte subpopulation cytotoxic to, human blood, 1520
–, human, chemotaxis, lymphocyte-derived factor, 1188
–, human, immunologic characterization of membrane collagen, 145

G

G_{IX} cell surface antigen, autoimmunization, 533
Gene complex, *H-2*, regulation of macrophage-lymphoid cell interactions, secondary antibody responses, 371
– control, *H-2*-linked immune response, *H-2D*-associated T-cell-mediated lympholysis to trinitrophenyl-modified autologous cells, 1701
– control of mating preferences, major histocompatibility complex, 1324
– control, suppression of antibody response, antigen-specific T cell factor, 20
– mapping, Ia determinants on concanavalin A-reactive cells, *I-J* subregion of *H-2* complex, 1141
– subregion assignment in *H-2* histocompatibility complex, suppressor T cell factor, 713
Genes, *H-2* complex complementing, immune suppression by copolymer (Glu,Tyr), 272
Genetic aspects, xenogeneic mixed leukocyte culture reaction, 305
– control, antibody response to $H\text{-}2D^b$ alloantigens, 266
– control of immune response, specific inhibition of antigen-induced lymphocyte proliferation by anti-idiotypic antibodies, 226
– control, immune suppression by copolymer (Glu,Tyr), cyclophosphamide-induced responses, 277
– control immune suppression by copolymer (Glu,Tyr), mapping of *H-2* complex complementing genes, 272
– linkage between human *C2* and *Bf*, 1111
– polymorphism, mouse immunoglobulin light chains, 298
– regulation, antibody response to $H\text{-}2D^b$ alloantigens, inhibition of IgG response to noncongenic cells, 654
– variability of serum protein SAA response to endotoxins and casein, amyloidosis, 1121
Genetics, idiotype of myeloma protein S117, Group A streptococcal carbohydrate, multiple chromosomal loci for V_H genes, 1164
β1H Globulin, modulation of alternative complement pathway, 1147
Glomerulonephritis, membranous, induction by nephritogenic tubular antigen, 1347
Glomerulus, basement membrane, interaction with DNA and collagen, systemic lupus erythematosus, 428
Graft survival, H-Y, effect of allogeneic sensitization, 810
–, thymus, or lipid A, IgG induction, nude mouse, 1031
Granules, human polymorphonuclear leukocytes, lymphocyte stimulation by neutral proteinases from, 863
Granulocytes, human, histamine release, 1049
Group-specific and type-specific protection against Group B meningococcal disease, chick embryo, 319
Growth, plasmacytoma, role of adherent cell substratum, 1554
– potential, spleen-colonizing bone marrow stem cells, aging mice, 1204

H

H-2 compatibility, virus-specific T cell-mediated cytolysis, regulation of immune response, 519
– complex complementing genes, immune suppression by copolymer (Glu,Tyr), 272
– complex, *I-J* subregion, gene mapping of Ia

determinants on concanavalin A-reactive cells, 1141
– complex, *K*- and *I*-region products, binding to T cells of different Ly subclasses, 1545
– gene complex, regulation of macrophage-lymphoid cell interactions, secondary antibody responses, 371
– histocompatibility complex, gene subregion assignment, suppressor T cell factor, 713
– incompatible target cells, trinitrophenyl-derivatized, cytolysis of by T lymphocytes, 1609
– (*I*-region) determinants on helper and suppressor T lymphocytes, 685
– *K* and *D* region, restriction of transfer of delayed-type hypersensitivity to lymphocytic choriomeningitis virus, 776
– linked immune response gene control, *H-2D*-associated T cell-mediated lympholysis to trinitrophenyl-modified autologous cells, 1701
– matched target cells modified by nitrophenyl compounds, cell-mediated lympholysis, 1134
– restriction of virus-specific cytotoxicity across barrier, chimeras, 933
– and *t* allele association, 834
– and TL alloantigens, β2-microglobulin association, lymphoid cells, 179
H-2^d T cells primed to antigen, cooperation with *H-2*^{k} cells, histocompatibility barrier, 1707
H-2D^b alloantigens, genetic control of antibody response to, 266
– alloantigens, genetic regulation of antibody response to, inhibition of IgG response to noncongenic cells, 654
Hapten-specific B cells, expression of Ia antigens, 414
– secondary B cell responses, allogeneic carrier-specific enhancement, 1254
Helper function, T cells depleted of alloantigen-reactive lymphocytes by in vivo filtration, failure to collaborte with allogeneic B cells, 617
– and suppressor T lymphocytes, *H-2 I*-region determinants, 685
– T cells, allotype-specific, removal by suppressor T cells, 330
Hemagglutinin antigenicity, monoclonal immune response to influenza virus, 985
Heme oxygenase, microsomal, catabolism of polychlorinated biphenyl-induced cytochrome P-448, 1509
Hemolytic complement, and major histocompatibility complex, chicken, 555
Herpes simplex, role of interferon, 1316
Histamine release, human granulocytes, 1049
Histocompatibility antigens, genetic control of immune response, specific inhibition of lymphocyte proliferation by anti-idiotypic antibodies, 226
– barrier, cooperation between *H-2*^{d} T cells primed to antigen and *H-2*^{k} cells, 1707
– complex, major, gene control of mating preferences, 1324
– complex, major, and serum hemolytic complement, chicken, 555
– *H-2* complex, gene subregion assignment, suppressor T cell factor, 713
HLA-D region antigens, primed LD typing, 549
H-Y graft survival, effect of allogeneic sensitization, 810
Hypercholesterolemia, familial, low density lipoprotein metabolism in lymphoid cells, 444
Hypersensitivity, delayed-type, and suppression, T cells, Ly and Ia antigens, 10
–, delayed-type, transfer to lymphocytic choriomeningitis virus, restriction by *H-2 K* and *D* regions, 776

I

I- and *K*-region products, *H-2* complex, binding to T cells of different Ly subclasses, 1545
Ia antigen and Fc receptors, T lymphocytes, 282
– antigen phenotypes, T cells, delayed-type hypersensitivity and suppression, 10
– antigen secretion, T cell subpopulation, 847
– antigens, expression of on hapten-specific B cells, 414
– determinants on concanavalin A-reactive cells, *I-J* subregion of *H-2* complex, 1141
Idiotypes, autogenous complementary, suppression by, first reponse priority, 946
– myeloma protein S117, Group A streptococcal carbohydrate, multiple chromosomal loci for V_H genes, 1164
I-J subregion of *H-2* complex, gene mapping of Ia determinants on concanavalin A-reactive cells, 1141
– subregion, surface determinant on suppressor T lymphocytes, 699
Imipramine, induction of immune response, effect of lymphocyte activation, 562
Immune precipitation and molecular weight characterization, mouse thymocyte Ly-3 antigens, 476
– response, effect of membrane stabilizing agents, lymphocyte activation, 562
– response, genetic control, specific inhibition of antigen-induced lymphocyte proliferation by anti-idiotypic antibodies, 226
– response, *H-2* compatibility for virus-specific T cell-mediated cytolysis, 519
– response, *H-2*-linked gene control, *H-2D*-associated T-cell-mediated lympholysis to trinitrophenyl-modified autologous cells, 1701
– response, monoclonal, to influenza virus, antigenicity of hemagglutinin, 985

– response to salmonella lipopolysaccharide, immunoglobulin synthesis and secretion by sheep lymphoid cells, 586
– response, T lymphocyte receptor for mixed lymphocyte reaction suppressor factor, 1214
– response and tolerance, role of self-carriers, haptenated syngeneic lymphoid cells, 1369
– responses, antigen recognition by T lymphocytes, 1641
– responses, structure of antigenic determinants leading to T lymphocyte stimulation, 1621
– suppression by copolymer (Glu,Tyr), cyclophosphamide-induced responses, 277
– suppression by copolymer (Glu, Tyr), mapping of *H-2* complex complementing genes, 272
Immunity, cell-mediated, role of T cells in antigen-induced B cell activation, 1175
–, cellular mediator of, T cell inhibition by Newcastle disease virus, 627
Immunization, phosphorylcholine, equivalent clonotypes, 1294
–, polypeptide, antibody response, tetraparental mice, 123
Immunocompetence, lymphocytes binding fluoresceinated antigens, 69
Immunoglobulin A myeloma, human, suppression of leukocyte chemotaxis, 1227
– coated anti-IgG B lymphocytes, interaction with macrophages, 788
– density, B lymphocyte surface, ontogenetic development and organ distribution, 494
– density, B lymphocyte surface, X-linked defect, 507
– G and high avidity plaque-forming cells, loss of in aging mice, 1037
– G induction by lipid A or thymus grafts, nude mouse, 1031
– G- or M-dependent cytolytic lymphocytes, human blood plaque assay, 1375
– heavy chains, variable region subgroups, serological detection, 897
– light chains, genetic polymorphism, 298
– M and IgD-like receptors, antigen-induced cocapping, B cells, 852
– response to *H-2D*^{b} alloantigens, inhibition of noncongenic cells, 654
–, surface, and Fc receptors, mitogenesis inactivation by interactions with, B lymphocytes, 882
–, surface, human neoplastic lymphocytes, anti-idiotype sera, 960
–, surface redistribution, motile B lymphocytes, 1683
– synthesis, inhibition by human B cell antiserum, 113
– synthesis and secretion, sheep lymphoid cells, primary response to salmonella lipopolysaccharide, 586
Immunologic characterization, membrane collagen, human fibroblasts, 145
Infection, encephalomyocarditis, role of interferon, 1305
–, Group B meningococcal, group-specific and type-specific protection, chick embryo, 319
Influenza, role of interferon, 1316
– virus, monoclonal immune response to, antigenicity of hemagglutinin, 985
Initiating factor, properdin-independent function, complement alternate pathway, 1062
Interferon, role in virus diseases, 1305,1316
I-region, *H-2* loci, determinants on helper and suppressor T lymphocytes, 685
Isoantiserum augmentation, lymphocyte-mediated cytotoxicity, 1284
Isoelectric focusing, genetic polymorphism, mouse immunoglobulin light chains, 298

K

K and *D* region, *H-2*, restriction of transfer of delayed-type hypersensitivity to lymphocytic choriomeningitis virus, 776
– and *I*-region products, *H-2* complex, binding to T cells of different Ly subclasses, 1545

L

Lactoferrin, human, binding to mouse peritoneal cells, 1567
LD typing, HLA-D region antigens, 549
Leukemia, AKR thymocytes, cell surface antigens, age-related changes, 193
– cells, lymphocytic and myelocytic, human B lymphocyte antigens, 167
– marrow cells, antibodies to oncornavirus-like proteins from, 1243
–, radiation, lack of ecotropic virus expression in lymphomas, 1406
–, radiation, lack of serological evidence for role of endogenous ecotropic viruses, 1391
Leukocyte chemotaxis, suppression of by human IgA myeloma components, 1227
– granules, human polymorphonuclear, lymphocyte stimulation by neutral proteinases from, 863
Leukocytes, xenogeneic, mixed culture reaction, genetic and cellular aspects, 305
Lidocain, induction of immune response, effect of lymphocyte activation, 562
Lipid A bound polypeptide, LPS-initiated mitogenesis, spleen cells, 840
– A or thymus grafts, IgG induction, nude mouse, 1031
–, skin, and cholesterol, suppression of antistreptolysin O response, 754
Lipopolysaccharide-initiated mitogenesis, lipid A bound polypeptide, spleen cells, 840
Lipopolysaccharides, salmonella, primary response to, immunoglobulin synthesis and secretion by sheep lymphoid cells, 586
Lipoprotein, low density, metabolism in lymphoid cells, familial hypercholesterolemia, 444
Locus, *H-2 I*-region, determinants on helper and suppressor T lymphocytes, 685
–, *Ia-4*, surface determinant on suppressor T lymphocytes, 699

Lupus erythematosus, systemic, interactions of DNA, collagen, and glomerular basement membrane, 428
Ly antigen phenotypes, T cells, delayed-type hypersensitivity and suppression, 10
– phenotype for syngeneic tumor, cytotoxic T cells, 1116
– subclasses, T cells, binding of *K*- and *I*-region products of *H-2* complex, 1545
Ly1 and Ly23 subclasses, T cells, independent pathways, 1128
Ly-3 antigens, mouse thymocytes, immune precipitation and molecular weight characterization, 476
Lymph nodes, lymphocyte homing into, affinity for high-endothelial venules, 828
Lymphocyte activation, effect of membrane stabilizing agents on immune response, 562
– activation, effect of sodium butyrate, 1674
– function, modulation by macrophage secretion, 155
– polyclonal activator, B cell mitogen, endotoxin protein, 821
– proliferation, antigen-induced, specific inhibition by anti-idiotypic antibodies, 226
– stimulation and inhibition by concanavalin A, 1494
Lymphocyte-derived factor, human fibroblast chemotaxis, 1188
Lymphocyte-mediated cytotoxicity, isoantiserum augmentation, 1284
Lymphocytes, affinity for high-endothelial venules, in vitro homing into lymph nodes, 828
–, alloantigen-reactive, helper function of T cells depleted of by in vivo filtration, 617
–, B, antigen-binding, requirement for extracellular antigen in cultures of, 568
–, B, anti-immunoglobulin IgG-coated, interaction with macrophages, 788
–, B, Fc receptor-mediated inhibition of activation, 768
–, B, human, antigens in lymphocytic and myelocytic leukemia cells, 167
–, B, human, Ia-like antiserum, inhibition of antibody-dependent cytotoxicity and immunoglobulin synthesis, 113
–, B, human, polyclonal activation, direct plaque-forming cell assay, 674
–, B, human, specific cell surface antigen, 98
–, B, mitogenesis inactivation, interactions with surface immunoglobulin and Fc receptors, 882
–, B, motile, surface immunoglobulin redistribution, 1683
–, B, surface immunoglobulin density, ontogenetic development and organ distribution, 494
–, B, X-linked defect, CBA/N mice, surface immunoglobulin density, 507
–, blood, human, induction of antibody response, 573
–, cytolytic IgG- or IgM-dependent, human blood plaque assay, 1375
–, human neoplastic, anti-idiotype sera against surface immunoglobulin, 960
–, immunocompetent, isolation of, antifluorescein affinity columns, 69
–, membrane transport, adenosine and thymidine, 1009
–, stimulation by neutral proteinases from human polymorphonuclear leukocyte granules, 863
– subpopulation, human blood, cytotoxicity for autologous fibroblasts, 1520
–, T, antigen recognition, 1641
–, T, cytolysis of trinitrophenyl-derivatized *H-2* incompatible target cells, 1609
–, T, cytotoxic, role of non-T cells, 241
–, T, Fc receptor, mixed reaction and cell-mediated lympholysis, 54
–, T, helper and suppresssor, *H-2 I*-region determinants, 685
–, T, human, fractionation on wheat germ agglutinin-Sepharose, 1381
–, T, human milk, 358
–, T, Ia antigen and Fc receptors, 282
–, T, precursor and mature, synergy in response to concanavalin A, 456
–, T, primary response to soluble protein antigens, 1263
–, T, receptor for mixed lymphocyte reaction suppressor factor, 1214
–, T, stimulation, structure of antigenic determinants, 1621
–, T, suppressor, surface determinant, *I-J* subregion, 699
Lymphocytic choriomeningitis virus, transfer of delayed-type hypersensitivity, restriction by *H-2 K* and *D* region, 776
Lymphoid cell-macrophage interactions, regulation by *H-2* gene complex, secondary antibody responses, 371
– cells, haptenated syngeneic, role of self-carriers in immune response and tolerance, 1369
– cells, low density lipoprotein metabolism, familial hypercholesterolemia, 444
– cells, β2-microglobulin association with *H-2* and TL alloantigens, 179
– cells, sheep, immunoglobulin synthesis and secretion, primary response to salmonella lipopolysaccharide, 586
Lymphokine synthesis, B cells, role of antigen-activated T cells, 1175
Lympholysis, cell-mediated, Fc receptor of T lymphocytes, 54
–, cell-mediated, *H-2* matched target cells modified by nitrophenyl compounds, 1134
–, T-cell-mediated, *H-2D* associated, trinitrophenyl-modified autologous cells, *H-2*-linked immune response gene control, 1701
Lymphoma size, role in antibody-mediated suppression, 1274
–, radiation leukemia, lack of ecotropic virus expression, 1406

Lysis of RNA tumor viruses, human serum complement, 970
Lysosomes, primary and secondary, alveolar macrophages, 920

M

M protein, streptococcal, extraction by nonionic detergent, antiphagocytic and type-specific molecules 32
α_2-Macroglobulin, human vascular endothelium, 1
Macrophage interaction with anti-immunoglobulin IgG-coated B lymphocytes, 788
– plasminogen activator, induction by asbestos blocked by anti-inflammatory steroids, 1689
– secretion, modulation of lymphocyte functions, 155
– spreading, role of coagulation factors and complement system, 1531
Macrophage-lymphoid cell interactions, regulation by *H-2* gene complex, secondary antibody responses, 371
Macrophages, adherent, role in plasmacytoma growth, 1554
–, alveolar, phagocytosis of tubular myelin, 906
–, alveolar, primary and secondary lysosomes, 920
–, peritoneal, 2-deoxyglucose inhibition of Fc and complement receptor-mediated phagocytosis, 1465
–, peritoneal, 2-deoxyglucose inhibition of phagocytosis and ATP generation, 1484
–, peritoneal, 5′-nucleotidase, cellular distribution and effects of endocytosis, 1596
–, peritoneal, 5′-nucleotidase, synthesis and degradation in resident and inflammatory populations, 1581
Mammary tumor virus, breeding test of backcross segregants, 1022
Man, B lymphocyte antigens, lymphocytic and myelocytic leukemia cells, 167
–, B lymphocyte Ia-like antiserum, inhibition of antibody-dependent cytotoxicity and immunoglobulin synthesis, 113
–, B lymphocyte polyclonal activation, direct plaque-forming cell assay, 674
–, B lymphocyte-specific cell surface antigen, 98
–, blood, lymphocyte subpopulation cytotoxic to autologous fibroblasts, 1520
–, blood lymphocytes, induction of antibody response, 573
–, blood, plaque assay of IgG- or IgM-dependent cytolytic lymphocytes, 1375
–, endothelial cells, basement membrane collagen synthesis, 209
–, erythrocytes, concanavalin A-mediated binding and sphering by monocytes, 1695
–, fibroblasts, chemotaxis, lymphocyte-derived factor, 1188
–, fibroblasts, immunologic characterization of membrane collagen, 145
–, genetic linkage between *C2* and *Bf*, 1111
–, granulocytes, histamine release, 1049
–, IgA myeloma, suppression of leukocyte chemotaxis, 1227
–, lactoferrin, binding to mouse peritoneal cells, 1567
–, malignant melanoma, cell surface antigens, serological typing with immune adherence assays, 873
–, milk, T lymphocytes, 358
–, neoplastic lymphocytes, anti-idiotype sera against surface immunoglobulin, 960
–, polymorphonuclear leukocyte granules, lymphocyte stimulation by neutral proteinases from, 863
–, serum complement, lysis of RNA tumor viruses, 970
–, T lymphocytes, fractionation on wheat germ agglutinin-Sepharose, 1381
–, vascular endothelium, α_2-macroglobulin, 1
Mapping, genes, Ia determinants on concanavalin A-reactive cells, *I-J* subregion of *H-2* complex, 1141
Mating preferences, control by genes in major histocompatibility complex, 1324
Mediator of cellular immunity, T cell inhibition by Newcastle disease virus, 627
Melanoma, human malignant, cell surface antigens, serological typing with immune adherence assays, 873
Membrane collagen, human fibroblasts, immunologic characterization, 145
–, glomerular basement, interaction with collagen and DNA, systemic lupus erythematosus, 428
– stabilizing agents, effect on immune response, effect of lymphocyte activation, 562
– transport, adenosine and thymidine, lymphocytes, 1009
Memory development, B cells, T cell requirements, 345
Meningococcal disease, Group B, group-specific and type-specific protection, chick embryo, 319
β2-Microglobulin association with *H-2* and TL alloantigens, lymphoid cells, 179
Microsomes, heme oxygenase catabolism of polychlorinated biphenyl-induced cytochrome P-448, 1509
Milk, human, T lymphocytes, 358
Mitogenesis inactivation, B lymphocytes, interactions with surface immunoglobulin and Fc receptors, 882
–, LPS-initiated, lipid A bound polypeptide, spleen cells, 840
Mixed lymphocyte reaction suppressor factor, T lymphocyte receptor for, 1214
Molecular weight characterization and immune precipitation, mouse thymocyte Ly-3 antigens, 476

Monoclonal immune response to influenza virus, antigenicity of hemagglutinin, 985
Monocytes, binding and sphering of concanavalin A-coated human red blood cells, 1695
Mouse, aging, decreased growth potential in spleen-colonizing bone marrow stem cells, 1204
–, amplifier and suppressor T cells, 398
–, B cell subpopulations responsive to T-dependent and T-independent antigens, 382
–, CBA/N, X-linked B lymphocyte defect, surface immunoglobulin density, 507
–, equivalent clonotypes, phosphorylcholine immunization, 1294
–, mating preferences, control by genes in major histocompatibility complex, 1324
–, nude, IgG induction by lipid A or thymus grafts, 1031
–, NZB/NZW adult, loss of suppressor T cells, 662
–, parental and F_1 hybrid strains, correlation of suppressor cell development, 1363
–, peritoneal cells, binding of human lactoferrin, 1567
–, tetraparental, antibody response to polypeptide immunization, 123
– thymocyte Ly-3 antigens, immune precipitation and molecular weight characterization, 476
Muscle acetylcholine receptor and antibody-receptor complex, autoimmune myasthenia gravis, 726
Myelin, tubular, phagocytosis of, alveolar macrophages, 906
Myeloma, IgA, human, suppression of leukocyte chemotaxis, 1227
– protein S117, genetics of idiotype, Group A streptococcal carbohydrate, multiple chromosomal loci for V_H genes, 1164
Myasthenia gravis, autoimmune, passive transfer with anti-acetylcholine receptor antibodies, 739
– gravis, autoimmune, syngeneic muscle acetylcholine receptor and antibody-receptor complex, 726

N

Neoplasm, human lymphocytes, anti-idiotype sera against surface immunoglobulin, 960
Nephritogenic tubular antigen, induction of membranous glomerulonephritis, 1347
Neurons, subthalamic and caudate nuclei, reactive antibodies, in chorea and acute rheumatic fever, 1094
Newcastle disease, role of interferon, 1316
– disease virus, inhibition of T cells, 627
Nitrophenyl modification of *H-2* matched target cells, cell-mediated lympholysis, 1134
5′-Nucleotidase, mouse peritoneal macrophages, cellular distribution and effects of endocytosis, 1596
–, mouse peritoneal macrophages, synthesis and degradation in resident and inflammatory populations, 1581

O

Oncogenesis, blood group carbohydrate chains, 644
Oncornavirus-like proteins, leukemic marrow cells, antibodies to, 1243
Ontogenesis, blood group carbohydrate chains, 644
Ontogenetic development and organ distribution, B lymphocyte surface immunoglobulin density, 494
Ontogeny, B cells, clonal diversity in chicken bursa, 79
Organ distribution and ontogenetic development, B lymphocyte surface immunoglobulin density, 494
Organophosphorus inhibitors, activation of serine esterases (proteases) in platelet secretion, 1657

P

Passive transfer, autoimmune myasthenia gravis, anti-acetylcholine receptor antibodies, 739
Peritoneal cells, mouse, binding of human lactoferrin, 1567
– macrophages, 2-deoxyglucose inhibition of Fc and complement receptor-mediated phagocytosis, 1465
– macrophages, 2-deoxyglucose inhibition of phagocytosis and ATP generation, 1484
– macrophages, 5′-nucleotidase, cellular distribution and effects of endocytosis, 1596
– macrophages, 5′-nucleotidase, synthesis and degradation in resident and inflammatory populations, 1581
Phagocytosis and ATP generation, inhibition by 2-deoxyglucose, peritoneal macrophages, 1484
–, Fc and complement receptor-mediated, peritoneal macrophages, inhibition by 2-deoxyglucose, 1465
–, macrophage interaction with anti-immunoglobulin IgG-coated B lymphocytes, 788
–, tubular myelin, alveolar macrophages, 906
Phenotype, Ly, for syngeneic tumor, cytotoxic T cells, 1116
Phosphorus, organic, inhibitors, activation of serine esterases (proteases) in platelet secretion, 1657
Phosphorylcholine immunization, equivalent clonotypes, 1294
Plaque assay, IgG- or IgM-dependent cytolytic lymphocytes, human blood, 1375
Plaque-forming cell assay, human B lymphocytes, polyclonal activation, 674
– cells, high avidity, and IgG, loss of in aging mice, 1037

Plasmacytoma growth, role of adherent cell substratum, 1554
Plasminogen activator, macrophage, induction by asbestos blocked by anti-inflammatory steroids, 1689
Platelet secretion, activation of serine esterases (proteases), organophosphorus inhibitors, 1657
Polychlorinated biphenyls, induction of cytochrome P-448, catabolism by microsomal heme oxygenase, inhibition of δ-aminolevulinate dehydratase, 1509
Polyclonal activation, human B lymphocytes, direct plaque-forming cell assay, 674
– activator of lymphocytes, B cell mitogen, endotoxin protein, 821
Polymorphism, genetic linkage between human *C2* and *Bf*, 1111
–, genetic, mouse immunoglobulin light chains, 298
Polypeptide immunization, antibody response, tetraparental mice, 123
–, lipid A bound, LPS-initiated mitogenesis, spleen cells, 840
Precipitation, immune, and molecular weight characterization, mouse thymocyte Ly-3 antigens, 476
Properdin, precursor, recruitment by labile C3/C5 convertase, complement alternate pathway, 1076
Properdin-independent initiating factor, complement alternate pathway, 1062
Proteases, activation of in platelet secretion, organophosphorus inhibitors, 1657
Protein antigens, T lymphocyte primary response, 1263
–, endotoxin, B cell mitogen, polyclonal activator of lymphocytes, 821
–, M, streptococcal, extraction by nonionic detergent, antiphagocytic and type-specific molecules, 32
–, myeloma S117, genetics of idiotype, Group A streptococcal carbohydrate, multiple chromosomal loci for V_H genes, 1164
–, oncornavirus-like, leukemic marrow cells, antibodies to, 1243
– SAA, amyloid A antiserum, albumin complex, 1679
– SAA, amyloid-related, connective tissue origin, 1336
– SAA, serum response to endotoxins and casein, genetic variability, amyloidosis, 1121
Proteinases, neutral, from human polymorphonuclear leukocyte granules, lymphocyte stimulation, 863
Prothymocytes, terminal deoxynucleotidyl transferase, 543

R

Radiation leukemia, lack of ecotropic virus expression in lymphomas, 1406
– leukemia, lack of serological evidence for role of endogenous ecotropic viruses, 1391
Reaginic antibody, contact sensitivity, 1386
– antibody formation, suppression with anti-μ antiserum, 288
Receptor, acetylcholine, antibody-receptor complex, muscles in autoimmune myasthenia gravis, 726
–, anti-acetylcholine antibodies, passive transfer of autoimmune myasthenia gravis, 739
–, antigen-binding, idiotypic, autoimmunization, transplantation tolerance, 1438
–, Fc, and Ia antigen, T lymphocytes, 282
–, Fc, inhibition of B lymphocyte activation, 768
–, Fc, and surface immunoglobulins, mitogenesis inactivation by interactions with, B lymphocytes, 882
–, Fc, T lymphocytes, mixed reaction and cell-mediated lympholysis, 54
–, IgM and IgD-like, antigen-induced cocapping, B cells, 852
–, T lymphocyte, for mixed lymphocyte reaction suppressor factor, 1214
Rheumatic fever, acute, antibodies reactive to subthalamic and caudate nuclei neurons, 1094
RNA tumor virus, lysis by human serum complement, 970

S

SAA protein, amyloid A antiserum, albumin complex, 1679
– protein, amyloid-related, connective tissue origin, 1336
–, serum protein response to endotoxins and casein, genetic variability, amyloidosis, 1121
Salmonella lipopolysaccharides, primary response to, immunoglobulin synthesis and secretion by sheep lymphoid cells, 586
Sarcoma, Moloney, role of interferon, 1316
Self-carriers, role in immune response and tolerance, haptenated syngeneic lymphoid cells, 1369
Sensitivity, contact, reaginic antibody, 1386
Sensitization, allogeneic, and H-Y graft survival, cell-mediated responses to H-Y antigen, 810
Sepharose-wheat germ agglutinin fractionation of human T lymphocytes, 1381
Serine esterases (proteases), activation of in platelet secretion, organophosphorus inhibitors, 1657
Serological detection, variable region subgroups of Ig heavy chains, 897
– evidence, lack of for role of endogenous ecotropic viruses in pathogenesis of radiation leukemia, 1391
– typing with immune adherence assays, human malignant melanoma surface antigens, 873
Serum antibodies to oncornavirus-like pro-

teins, leukemic marrow cells, 1243
–, anti-idiotype, against surface immunoglobulin, human neoplastic lymphocytes, 960
–, anti-interferon, pathogenesis of virus diseases, 1305,1316
– hemolytic complement and major histocompatibility complex, chicken, 555
–, human, complement lysis of RNA tumor viruses, 970
– protein, amyloid A, antiserum to SAA, albumin complex, 1679
– protein SAA response to endotoxins and casein, genetic variability, amyloidosis, 1121
Sheep lymphoid cells, immunoglobulin synthesis and secretion, primary response to salmonella lipopolysaccharide, 586
Size, tumor, role in antibody-mediated suppression of grafted lymphoma, 1274
Skin lipids and cholesterol, suppression of antistreptolysin O response, 754
Sodium butyrate, effect on lymphocyte activation, 1674
Sphering and binding of concanavalin A-coated human red blood cells by monocytes, 1695
Spleen cells, cytotoxicity, adsorptive behavior of effectors, 996
– cells, lipid A bound polypeptide, LPS-initiated mitogenesis, 840
– cells, neonatal and adult susceptibility to induction of B cell tolerance, 293
– colonizing bone marrow stem cells, aging mice, decreased growth potential, 1204
Spreading, macrophage, role of coagulation factors and complement system, 1531
Stem cells, bone marrow, spleen-colonizing, aging mice, decreased growth potential, 1204
Steroids, anti-inflammatory, effect on asbestos induction of macrophage plasminogen activator, 1689
Stomatitis, vesicular, role of interferon, 1316
Streptococcus, Group A, carbohydrate, myeloma protein S117, multiple chromosomal loci for V_H genes, 1164
–, M protein extraction by nonionic detergent, antiphagocytic and type-specific molecules, 32
Substratum, adherent, role in plasmacytoma growth, 1554
Subthalamic and caudate nuclei neurons, reactive antibodies, in chorea and acute rheumatic fever, 1094
Suppression of antibody-response, gene control, antigen-specific T cell factor, 20
– of antistreptolysin O response by cholesterol and skin lipids, 754
– by autogenous complementary idiotypes, first response priority, 946
– and delayed-type hypersensitivity, T cells, Ly and Ia antigens, 10
–, immune, by copolymer (Glu,Tyr), cyclophosphamide-induced responses, 277
–, immune, by copolymer (Glu,Tyr), mapping of *H-2* complex complementing genes, 272
– of leukocyte chemotaxis, human IgA myeloma components, 1227
– of reaginic antibody formation, anti-μ antiserum, 288
– by syngeneic antibody of grafted lymphoma, role of time and tumor size, 1274
Suppressor and amplifier T cells, murine subpopulations, 398
– cell development, correlation in parental and F_1 hybrid mouse strains, anti-tumor response, 1363
– cell, increased activity in aging mice, 1037
– factor, mixed lymphocyte reaction, T lymphocyte receptor for, 1214
– and helper T lymphocytes, *H-2 I*-region determinants, 685
– T cell factor, antigen-specific, subregion gene assignment in *H-2* histocompatibility complex, 713
– T cells, loss of in adult NZB/NZW mice, 662
– T cells, removal of allotype-specific helper T cells, 330
– T lymphocytes, surface determinant, *I-J* subregion, 699
Surface antigen, G_{IX} cell, autoimmunization, 533
– antigen, human B lymphocyte-specific, 98
– antigen, human malignant melanoma, serological typing with immune adherence assays, 873
– antigen, preleukemic AKR thymocytes, age-related changes, 193
– determinant on suppressor T lymphocytes, *I-J* subregion, 699
– immunoglobulin density, B lymphocytes, X-linked defect, 507
– immunoglobulin and Fc receptors, mitogenesis inactivation by interactions with, B lymphocytes, 882
– immunoglobulin, human neoplastic lymphocytes, anti-idiotype sera, 960
– immunoglobulin redistribution, motile B lymphocytes, 1683
Syngeneic and allogeneic erythrocyte conjugates, antihapten antibody production, T cell deficiency, 467
– antibody suppression of grafted lymphoma, role of time and tumor size, 1274
– lymphoid cells, haptenated, role of self-carriers in immune response and tolerance, 1369
– muscle acetylcholine receptor and antibody-receptor complex, autoimmune myasthenia gravis, 726
– tumor, Ly phenotype, cytotoxic T cells, 1116
Synergy, response of precursor and mature T lymphocytes to concanavalin A, 456

T

T antigens, dependent and independent, murine B cell subpopulations responsive to, 382
– cell deficiency, antihapten antibody production against syngeneic and allogeneic erythrocyte conjugates, 467
– cell factor, antigen-specific, gene control of suppression of antibody response, 20
– cell regulation of antibody responses, allotype-specific helper T cells, removal by suppressor T cells, 330
– cell requirements, B cell memory development, 345
– cell subpopulation, Ia antigen secretion, 847
– cell suppressor factor, antigen-specific, subregion gene assignment in *H-2* histocompatibility complex, 713
– cell-mediated lympholysis, *H-2D* associated, trinitrophenyl-modified autologous cells, *H-2*-linked immune response gene control, 1701
– cells, amplifier and suppressor, murine subpopulations, 398
– cells, cytotoxic, Ly phenotype for syngeneic tumor, 1116
– cells depleted of alloantigen-reactive lymphocytes by in vivo filtration, helper function of, 617
– cells, $H\text{-}2^d$ primed to antigen, cooperation with $H\text{-}2^k$ cells, histocompatibility barrier, 1707
– cells, independent pathways of Ly1 and Ly23 subclasses, 1128
– cells, inhibition by Newcastle disease virus, 627
– cells, Ly and Ia antigens, delayed-type hypersensitivity and suppression, 10
– cells, Ly subclasses, binding of *K*- and *I*-region products of *H-2* complex, 1545
– cells, role in antigen-induced B cell activation, 1175
– cells, suppressor, loss of in adult NZB/NZW mice, 662
– cells, virus-specific cytolysis, *H-2* compatibility, 519
– cells, virus-specific effector function, *H-2* restriction of, 776
t factors, association with alleles at *H-2*, 834
T lymphocyte receptor, for mixed lymphocyte reaction suppressor factor, 1214
– lymphocyte stimulation, structure of antigenic determinants, 1621
– lymphocytes, antigen recognition, 1641
– lymphocytes, cytolysis of trinitrophenyl-derivatized *H-2* incompatible target cells, 1609
– lymphocytes, cytotoxic, role of non-T cells, 241
– lymphocytes, Fc receptor, mixed reaction and cell-mediated lympholysis, 54
– lymphocytes, helper and suppressor, *H-2 I*-region determinants, 685
– lymphocytes, human, fractionation on wheat germ agglutinin-Sepharose, 1381
– lymphocytes, human milk, 358
– lymphocytes, Ia antigen and Fc receptors, 282
– lymphocytes, precursor and mature, synergy in response to concanavalin A, 456
– lymphocytes, primary response to soluble protein antigens, 1263
– lymphocytes, suppressor, surface determinant, *I-J* subregion, 699
Target cells, *H-2* incompatible, trinitrophenyl-derivatized, cytolysis of by T lymphocytes, 1609
– cells, *H-2* matched, modified by nitrophenyl compounds, cell-mediated lympholysis, 1134
Tetraparental mice, antibody response to polypeptide immunization, 123
Tetrapeptides, acidic, structural determinants, eosinophil chemotactic factor of anaphylaxis, 1424
Thymidine and adenosine, membrane transport, lymphocytes, 1009
Thymocytes, mouse, Ly-3 antigens, immune precipitation and molecular weight characterization, 476
–, preleukemic AKR, cell surface antigens, age-related changes, 193
–, terminal deoxynucleotidyl transferase, 543
Thymus grafts or lipid A, IgG induction, nude mouse, 1031
Time, role in antibody-mediated suppression of grafted lymphoma, 1274
TL and *H-2* alloantigens, lymphoid cells, β2-microglobulin association, 179
Tolerance, B cells, neonatal and adult spleen cell susceptibility to induction of, 293
– and immune response, role of self-carriers, haptenated syngeneic lymphoid cells, 1369
–, transplantation, induction by autoimmunization against idiotypic antigen-binding receptors, 1438
Transplantation tolerance, induction by autoimmunization against idiotypic antigen-binding receptors, 1438
Trinitrophenyl-derivatized *H-2* incompatible target cells, cytolysis of by T lymphocytes, 1609
Tubular antigen, nephritogenic, induction of membranous glomerulonephritis, 1347
– myelin, phagocytosis of, alveolar macrophages, 906
Tumor suppression, antibody-mediated, 1274
–, syngeneic, Ly phenotype, cytotoxic T cells, 1116
– virus, mammary, breeding test of backcross segregants, 1022

– virus, RNA, lysis by human serum complement, 970
Type-specific and antiphagocytic molecules, streptococcal M protein extraction by nonionic detergent, 32
– and group-specific protection against Group B meningococcal disease, chick embryo, 319

U

Unresponsiveness, induction and abrogation of, nude mouse cells, 1458

V

Variable region subgroups of Ig heavy chains, serological detection, 897
Vascular endothelium, human, α_2-macroglobulin, 1
Venules, high-endothelial, selective affinity of lymphocytes for, 828
Virus diseases, role of interferon, 1305,1316
–, ecotropic endogenous, role in pathogenesis of radiation leukemia, lack of serological evidence, 1391
–, ecotropic, lack of expression in lymphomas, radiation leukemia, 1406
–, influenza, monoclonal immune response to, antigenicity of hemagglutinin, 985
–, lymphocytic choriomeningitis, transfer of delayed-type hypersensitivity, restriction by *H-2 K* and *D* region, 776
–, mammary tumor, breeding test of backcross segregants, 1022
–, Newcastle disease, inhibition of T cells, 627
–, RNA tumor, lysis by human serum complement, 970
Virus-specific cytotoxicity, *H-2* restriction of across barrier, chimeras, 933
– T cell-mediated cytolysis, *H-2* compatibility, 519

W

Wheat germ agglutinin-Sepharose fractionation of human T lymphocytes, 1381

X

Xenogenic mixed leukocyte culture reaction, genetic and cellular aspects, 305
X-linked B lymphocyte defect, CBA/N mice, surface immunoglobulin density, 507

Statement of Ownership, Management, and Circulation required by Act of 12 August 1970; Section 3685, Title 39, United States Code: The Journal of Experimental Medicine. Published monthly at 1230 York Ave., New York 10021, by The Rockefeller University Press, New York 10021. Editors: Zanvil A. Cohn, James G. Hirsch, Henry G. Kunkel, Maclyn McCarty, The Rockefeller University, New York 10021. Owned by The Rockefeller University, New York 10021, nonprofit corporation, authorized to mail at special rates. Purpose, function, and nonprofit status of the organization and the exempt status for Federal income tax purposes have not changed during the preceding 12 months. Following statistics represent 12 month average and number nearest to date of filing: copies printed for each issue, 3790; sales through dealers, street vendors, counter sales, 0; mail subscriptions, 3527. Total paid circulation, 3527; free distribution, 67; office use, left-over, unaccounted, spoiled, 196; net press run, 3790. Single issue nearest filing date October 1976.